NZ713782B2 - Anti-il-4/anti-il-13 bispecific antibody formulations - Google Patents
Anti-il-4/anti-il-13 bispecific antibody formulations Download PDFInfo
- Publication number
- NZ713782B2 NZ713782B2 NZ713782A NZ71378214A NZ713782B2 NZ 713782 B2 NZ713782 B2 NZ 713782B2 NZ 713782 A NZ713782 A NZ 713782A NZ 71378214 A NZ71378214 A NZ 71378214A NZ 713782 B2 NZ713782 B2 NZ 713782B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- antibody
- phosphate
- tris
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 451
- 102000004965 antibodies Human genes 0.000 title claims abstract description 327
- 108090001123 antibodies Proteins 0.000 title claims abstract description 327
- 238000009472 formulation Methods 0.000 claims abstract description 237
- 201000010099 disease Diseases 0.000 claims abstract description 58
- 230000003139 buffering Effects 0.000 claims abstract description 57
- 239000011780 sodium chloride Substances 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000007983 Tris buffer Substances 0.000 claims description 195
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 172
- 239000005720 sucrose Substances 0.000 claims description 172
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 131
- 108090000978 Interleukin-4 Proteins 0.000 claims description 98
- 102000004388 Interleukin-4 Human genes 0.000 claims description 98
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 95
- 239000000427 antigen Substances 0.000 claims description 92
- 102000038129 antigens Human genes 0.000 claims description 92
- 108091007172 antigens Proteins 0.000 claims description 92
- 230000027455 binding Effects 0.000 claims description 87
- 108090000176 Interleukin-13 Proteins 0.000 claims description 86
- 102000003816 Interleukin-13 Human genes 0.000 claims description 86
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 60
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 60
- 239000000594 mannitol Substances 0.000 claims description 60
- 235000010355 mannitol Nutrition 0.000 claims description 60
- 239000008363 phosphate buffer Substances 0.000 claims description 28
- 229940068968 Polysorbate 80 Drugs 0.000 claims description 24
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 24
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 24
- 229920000053 polysorbate 80 Polymers 0.000 claims description 24
- 230000001404 mediated Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 208000006673 Asthma Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 5
- 101710024506 TH2 Proteins 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 abstract description 33
- 235000000346 sugar Nutrition 0.000 abstract description 29
- 239000002736 nonionic surfactant Substances 0.000 abstract description 18
- 239000010452 phosphate Substances 0.000 description 179
- 229960004793 Sucrose Drugs 0.000 description 170
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 166
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 156
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 153
- 238000004166 bioassay Methods 0.000 description 116
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 90
- 229960002429 Proline Drugs 0.000 description 85
- 239000000654 additive Substances 0.000 description 82
- 239000004471 Glycine Substances 0.000 description 80
- 229960002449 Glycine Drugs 0.000 description 80
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 79
- 230000015572 biosynthetic process Effects 0.000 description 71
- 238000005755 formation reaction Methods 0.000 description 68
- 229960002885 Histidine Drugs 0.000 description 61
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 60
- 235000014304 histidine Nutrition 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 57
- 229960001855 mannitol Drugs 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 229920001184 polypeptide Polymers 0.000 description 54
- 230000000694 effects Effects 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 50
- 230000000996 additive Effects 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 48
- 241000282414 Homo sapiens Species 0.000 description 47
- 150000001413 amino acids Chemical class 0.000 description 45
- 125000000539 amino acid group Chemical group 0.000 description 42
- 239000002245 particle Substances 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 41
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- 238000004108 freeze drying Methods 0.000 description 38
- 230000035882 stress Effects 0.000 description 37
- 238000000034 method Methods 0.000 description 36
- 229940024606 Amino Acids Drugs 0.000 description 24
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 24
- 239000007853 buffer solution Substances 0.000 description 23
- 108010071919 Bispecific Antibodies Proteins 0.000 description 22
- 239000007788 liquid Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 238000000113 differential scanning calorimetry Methods 0.000 description 21
- 229940086735 succinate Drugs 0.000 description 21
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 19
- 235000012970 cakes Nutrition 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 102000018358 Immunoglobulins Human genes 0.000 description 15
- 108060003951 Immunoglobulins Proteins 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 15
- 238000004220 aggregation Methods 0.000 description 15
- 238000011161 development Methods 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 239000004094 surface-active agent Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000003860 storage Methods 0.000 description 14
- 241000124008 Mammalia Species 0.000 description 13
- 229940009098 Aspartate Drugs 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 229920001850 Nucleic acid sequence Polymers 0.000 description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- -1 e.g. Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 206010003816 Autoimmune disease Diseases 0.000 description 10
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 10
- 102000004851 Immunoglobulin G Human genes 0.000 description 10
- 108090001095 Immunoglobulin G Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000000875 corresponding Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 230000000087 stabilizing Effects 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- 108010045030 monoclonal antibodies Proteins 0.000 description 9
- 102000005614 monoclonal antibodies Human genes 0.000 description 9
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 9
- 235000019799 monosodium phosphate Nutrition 0.000 description 9
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 9
- 150000008163 sugars Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 201000009910 diseases by infectious agent Diseases 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000003042 antagnostic Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 230000003247 decreasing Effects 0.000 description 7
- 239000012537 formulation buffer Substances 0.000 description 7
- 239000006174 pH buffer Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 229960002989 Glutamic Acid Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 6
- 229960003121 arginine Drugs 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 208000008787 Cardiovascular Disease Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 208000008466 Metabolic Disease Diseases 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 206010038683 Respiratory disease Diseases 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001082 cryoprotectant Effects 0.000 description 5
- 239000002577 cryoprotective agent Substances 0.000 description 5
- 230000004059 degradation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000000368 destabilizing Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229920001903 high density polyethylene Polymers 0.000 description 5
- 239000004700 high-density polyethylene Substances 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 230000000926 neurological Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000003019 stabilising Effects 0.000 description 5
- 238000011179 visual inspection Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 239000004695 Polyether sulfone Substances 0.000 description 4
- 229950008882 Polysorbate Drugs 0.000 description 4
- 102000014961 Protein Precursors Human genes 0.000 description 4
- 108010078762 Protein Precursors Proteins 0.000 description 4
- 101700082686 WFDC1 Proteins 0.000 description 4
- 102100017149 WFDC1 Human genes 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 108091006028 chimera Proteins 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960003136 leucine Drugs 0.000 description 4
- 230000003003 lyoprotectant Effects 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229920002496 poly(ether sulfone) Polymers 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000011165 process development Methods 0.000 description 4
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 229960002743 Glutamine Drugs 0.000 description 3
- 206010020243 Hodgkin's disease Diseases 0.000 description 3
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 3
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229940068965 Polysorbates Drugs 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 201000009961 allergic asthma Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000037030 denaturation temperature Effects 0.000 description 3
- 201000004624 dermatitis Diseases 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000019207 human interleukin-13 Human genes 0.000 description 3
- 108091018136 human interleukin-13 Proteins 0.000 description 3
- 230000002452 interceptive Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N 3-Mercaptopropane-1,2-diol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 229960003767 Alanine Drugs 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 208000003455 Anaphylaxis Diseases 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 229960005261 Aspartic Acid Drugs 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 210000003996 CFU-GM Anatomy 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 208000005679 Eczema Diseases 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N Guanosine monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 208000009856 Lung Disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 229960000502 Poloxamer Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010046736 Urticarias Diseases 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000172 allergic Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 201000006618 congenital myasthenic syndrome 6 Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 231100001003 eczema Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 235000013928 guanylic acid Nutrition 0.000 description 2
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920003208 poly(ethylene sulfide) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920003245 polyoctenamer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 239000011123 type I (borosilicate glass) Substances 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- HTCSFFGLRQDZDE-UHFFFAOYSA-N 2-azaniumyl-2-phenylpropanoate Chemical compound OC(=O)C(N)(C)C1=CC=CC=C1 HTCSFFGLRQDZDE-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000000659 Autoimmune Lymphoproliferative Syndrome Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 102000024969 Bacterial Proteins Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 201000011497 Barrett's esophagus Diseases 0.000 description 1
- 206010004137 Barrett's oesophagus Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- 206010072757 Chronic spontaneous urticaria Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000010247 Contact Dermatitis Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N Galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 101710007377 H1-4 Proteins 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N HCl HCl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010051040 Hyper IgE syndrome Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 229940027941 Immunoglobulin G Drugs 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940028885 Interleukin-4 Drugs 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 201000007313 Kawasaki disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N Lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 208000009928 Nephrosis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229940099511 POLYSORBATE 65 Drugs 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 230000037249 Plasma Binding Effects 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037391 Pulmonary granuloma Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N Ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229940046307 SODIUM THIOGLYCOLATE Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 201000006984 Sezary's disease Diseases 0.000 description 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N Stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 238000010928 TGA analysis Methods 0.000 description 1
- 210000004241 Th2 Cells Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940045136 Urea Drugs 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047931 Whipple's disease Diseases 0.000 description 1
- 229960003487 Xylose Drugs 0.000 description 1
- OQOQSRMIBLJVHE-UHFFFAOYSA-L [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O Chemical compound [K+].[K+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O OQOQSRMIBLJVHE-UHFFFAOYSA-L 0.000 description 1
- KNKDZWFHOIKECV-UHFFFAOYSA-L [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [K+].[K+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O KNKDZWFHOIKECV-UHFFFAOYSA-L 0.000 description 1
- KYOYLUVYCHVYGC-BUOKYLHBSA-M [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O Chemical compound [Na+].OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C([O-])=O KYOYLUVYCHVYGC-BUOKYLHBSA-M 0.000 description 1
- WGFMTHGYKYEDHF-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)=O.[O-]C(=O)C([O-])=O WGFMTHGYKYEDHF-UHFFFAOYSA-L 0.000 description 1
- GZLGNNHEHXBCBI-UHFFFAOYSA-L [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O Chemical compound [Na+].[Na+].OC(=O)C(O)C(O)C(O)=O.[O-]C(=O)C(O)C(O)C([O-])=O GZLGNNHEHXBCBI-UHFFFAOYSA-L 0.000 description 1
- SILCDLWESNHZKB-UHFFFAOYSA-L [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
- JYXKLAOSCQDVIX-NFMYELBMSA-K [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O Chemical compound [Na+].[Na+].[Na+].OC(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O JYXKLAOSCQDVIX-NFMYELBMSA-K 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 229960000539 carbamide Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 150000003999 cyclitols Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- MYSDBRXBYJKGLB-WOGKQDBSSA-L disodium;(E)-but-2-enedioate;(E)-but-2-enedioic acid Chemical compound [Na+].[Na+].OC(=O)\C=C\C(O)=O.[O-]C(=O)\C=C\C([O-])=O MYSDBRXBYJKGLB-WOGKQDBSSA-L 0.000 description 1
- FCNVPOALDDLXOR-UHFFFAOYSA-L disodium;benzoate;chloride Chemical compound [Na+].[Na+].[Cl-].[O-]C(=O)C1=CC=CC=C1 FCNVPOALDDLXOR-UHFFFAOYSA-L 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 201000003928 fungal infectious disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001969 hypertrophic Effects 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoide Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000011152 pemphigus Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- LCPMNMXCIHBTEX-UHFFFAOYSA-M potassium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [K+].CC(O)C(O)=O.CC(O)C([O-])=O LCPMNMXCIHBTEX-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000010850 salt effect Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
- VDZDAHYKYRVHJR-UHFFFAOYSA-M sodium;2-hydroxypropanoate;hydrate Chemical compound [OH-].[Na+].CC(O)C(O)=O VDZDAHYKYRVHJR-UHFFFAOYSA-M 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
- VBGUQBPWJMPQBI-UHFFFAOYSA-M sodium;butanedioic acid;4-hydroxy-4-oxobutanoate Chemical compound [Na+].OC(=O)CCC(O)=O.OC(=O)CCC([O-])=O VBGUQBPWJMPQBI-UHFFFAOYSA-M 0.000 description 1
- JISIBLCXFLGVJX-UHFFFAOYSA-M sodium;butanedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CCC(O)=O JISIBLCXFLGVJX-UHFFFAOYSA-M 0.000 description 1
- KIJIBEBWNNLSKE-UHFFFAOYSA-M sodium;oxalic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)C(O)=O KIJIBEBWNNLSKE-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases. order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases.
Description
ANTI-IL-4/ANTI-IL-13 BISPECIFIC ANTIBODY FORMULATIONS
FIELD OF THE INVENTION
The present invention provides stable pharmaceutical antibody formulations, including
lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering
system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low
salt concentration in order to reduce the ionic strength of the formulation. The formulations
may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing
agent. The formulations can be used in the treatment of various diseases.
BACKGROUND OF THE INVENTION
It is to be understood that if any prior art publication is referred to herein, such reference
does not constitute an admission that the publication forms a part of the common general
knowledge in the art in Australia or any other country.
Both IL-4 and IL-13 are therapeutically important cytokines based on their biological
functions and play critical roles in many diseases, including asthma (Curr Opin Allergy Clin
Immunol 2005, Vo. 5, 161-166). IL-4 has been shown to be able to inhibit autoimmune disease,
and IL-4 and IL-13 have both shown the potential to enhance anti-tumor immune responses.
Since both cytokines are involved in the pathogenesis of allergic diseases, inhibitors of these
cytokines could provide therapeutic benefits.
In order to develop a pharmaceutical formulation containing an anti-IL-4/anti-IL-13
bispecific antibody suitable for subcutaneous administration, the antibody must be concentrated
to about 100 mg/mL or greater. However, many complications can arise at such high
concentrations, including an increase in viscosity, a shift of pH, a change in the color of the
solution, and the formation of visible and sub-visible particles. Formulation of the antibody is
further complicated by the fact that it is highly prone to aggregation at high concentrations.
While typical antibodies normally form high molecular weight aggregates (HMW) below 5%
over a time period of 4 years at 5°C, the anti-IL-4/anti-IL-13 bispecific antibody forms HMW at
a rate of between 0.5-1% per hour at 25°C, and at 0.1% per hour at 5°C. Indeed, this antibody
has such a strong propensity to aggregate that it cannot be formulated in a liquid in the
concentration range targeted. Finally, the anti-IL4/anti-IL13 bispecific antibody has a
18169100_1 (GHMatters) P41154NZ00
particularly low isoelectric point, making it more difficult to formulate due to solubility issues.
For example, the anti-IL4/anti-IL13 bispecific antibody has an isoelectric point between 5.8 and
6.2, whereas most antibodies have an isoelectric point between 8 and 10.
Accordingly, a need exists for improved and stable pharmaceutical formulations that can
address one or more of these complications.
SUMMARY OF THE INVENTION
Provided herein are highly stable anti-IL-4/anti-IL-13 bispecific antibody formulations.
Highly stable anti-IL-4/anti-IL-13 bispecific antibody formulations have surprisingly been found
in the form of liquids and lyophilized powders that comprise an anti-IL-4/anti-IL-13 bispecific
antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein
the formulation has a low salt concentration in order to reduce the ionic strength of the
formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar,
and/or a non-ionic stabilizing agent. These formulations improve upon conventional
formulations, which often lead to molecular aggregation (HMW) of the antibody upon increasing
the concentration of the antibody in the formulation, and the formation of visible and sub-visible
particles. In particular, the formulations of the invention exhibit good stability regarding visible
particles, sub-visible particles, low molecular weight proteins, and high molecular weight
proteins.
An embodiment of the invention provides a stable antibody formulation comprising: a
bispecific anti-IL-4/anti-IL-13 antibody or an antigen binding fragment thereof, comprising a
light chain of the formula VL1-linker-VL2 and a heavy chain of the formula VH1-linker-VH2,
wherein VL1 and VH1 form an IL-13 antigen binding domain and VL2 and VH2 form an IL-4
antigen binding domain; and a buffering system suitable to maintain the pH of the formulation at
about pH 7; and wherein the formulation has a low salt concentration in order to reduce the ionic
strength of the formulation.
In specific embodiments, VL1 comprises the CDR sequences of SEQ ID NO: 1; VH1
comprises the CDR sequences of SEQ ID NO: 2; VL2 comprises the CDR sequences of SEQ ID
NO: 3; and VH2 comprises the CDR sequences of SEQ ID NO: 4 or 5. In alternative specific
embodiments, VL1 comprises the amino acid sequence of SEQ ID NO: 1; VH1 comprises the
18169100_1 (GHMatters) P41154NZ00
amino acid sequence of SEQ ID NO: 2; VL2 comprises the amino acid sequence of SEQ ID NO:
3; and VH2 comprises the amino acid sequence of SEQ ID NO: 4 or 5.
According to an aspect of the invention, there is provided a stable antibody formulation
comprising 100 mg/mL of a bispecific anti-IL-4/anti-IL-13 antibody, comprising a light chain of
the formula VL1-linker-VL2 and a heavy chain of the formula VH1-linker-VH2, wherein VL1
and VH1 form an IL-13 antigen binding domain and VL2 and VH2 form an IL-4 antigen binding
domain, wherein VL1 comprises the CDR sequences of SEQ ID NO: 1; VH1 comprises the CDR
sequences of SEQ ID NO: 2; VL2 comprises the CDR sequences of SEQ ID NO: 3; and VH2
comprises the CDR sequences of SEQ ID NO: 4 or 5; and a buffering system suitable to
maintain the pH of the formulation at pH 7, wherein the buffering system comprises Tris buffer
and phosphate buffer and wherein the formulation has a salt concentration of 10 mM in order to
reduce the ionic strength of the formulation; 0.05% to 0.2% (w/v) polysorbate 80 at a
concentration; 5% (w/v) sucrose; and 1% to about 3% (w/v) mannitol.
In specific embodiments, the light chain comprises the formula N-VL1-linker-VL2-CL,
wherein CL is a light chain constant domain of an antibody, and wherein the heavy chain
comprises the formula N-VH1-linker-VH2-CH1-CH2-CH3, wherein CH2-CH3 corresponds to
the Fc domain of an antibody. In specific embodiments, the linker comprises the amino acid
sequence of SEQ ID NO: 6.
In specific embodiments, the antibody or antigen binding fragment thereof further
comprises a constant region domain. In specific embodiments, the constant region domain is
selected from the group consisting of CH1, CH2, CH3, and CL.
In specific embodiments, the bispecific antibody or antigen binding fragment thereof is a
humanized IgG4 bispecific antibody or antigen binding fragment thereof.
In specific embodiments, the concentration of antibody or antigen binding fragment
thereof is about 100 mg/mL.
In certain embodiments of the invention, the buffering system comprises at least two
buffers. In specific embodiments, the buffering system concentration is about 10 mM. In
specific embodiments, the buffering system comprises Tris buffer and Phosphate buffer. In
specific embodiments, the Tris buffer concentration is about 3.7 mM. In specific embodiments,
the Phosphate buffer concentration is about 6.3 mM. In specific embodiments, the Tris buffer
concentration is about 3.7 mM and the Phosphate buffer concentration is about 6.3 mM.
18169100_1 (GHMatters) P41154NZ00
In certain embodiments of the invention, the formulation further comprises a non-ionic
surfactant. In specific embodiments, the non-ionic surfactant concentration is about 0.05% to
about 0.2% (w/v). In specific embodiments, the non-ionic surfactant is a polysorbate. In
specific embodiments, the polysorbate is polysorbate 80. In specific embodiments, the
polysorbate 80 concentration is about 0.05% to about 0.2% (w/v). In specific embodiments, the
polysorbate 80 concentration is about 0.2% (w/v).
In certain embodiments of the invention, the formulation further comprises a sugar. In
specific embodiments, the sugar concentration is about 5% (w/v). In specific embodiments, the
sugar is a disaccharide. In specific embodiments, the disaccharide is sucrose. In specific
embodiments, the sucrose concentration is about 5% (w/v).
In certain embodiments of the invention, the formulation further comprises a non-ionic
stabilizing agent. In specific embodiments, the non-ionic stabilizing agent concentration is about
1% to about 3% (w/v). In specific embodiments, the non-ionic stabilizing agent is either an
amino acid or a sugar. In specific embodiments, the amino acid is proline. In specific
embodiments, the sugar is mannitol. In specific embodiments, the proline concentration is about
1% to about 3% (w/v). In specific embodiments, the proline concentration is about 3% (w/v). In
specific embodiments, the mannitol concentration is about 3% (w/v).
In certain embodiments of the invention, the formulation is a lyophilized formulation.
In certain embodiments of the invention, the formulation exhibits good stability regarding
visible particles, sub-visible particles, low molecular weight proteins, and high molecular weight
proteins.
An embodiment of the invention provides a stable lyophilized antibody formulation
comprising: about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3; about 10 mM of a
buffering system, wherein the buffering system comprises a Tris buffer concentration of about
3.7 mM and a Phosphate buffer concentration of about 6.3 mM; about 0.2% (w/v) polysorbate
80; about 5% (w/v) sucrose; and about 3% (w/v) proline; wherein the pH of the formulation is
about pH 7.
18169100_1 (GHMatters) P41154NZ00
An embodiment of the invention provides a stable lyophilized antibody formulation
comprising: about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3; about 10 mM of a
buffering system, wherein the buffering system comprises a Tris buffer concentration of about
3.7 mM and a Phosphate buffer concentration of about 6.3 mM; about 0.2% (w/v) polysorbate
80; about 5% (w/v) sucrose; and about 3% (w/v) mannitol; wherein the pH of the formulation is
about pH 7.
An embodiment of the invention provides a kit comprising a container comprising a
formulation of the invention and instructions for the administration and use of the formulation.
An embodiment of the invention provides a method for treating an allergic disease,
cancer, asthma, a disease associated with abnormal production of IL-4 and/or IL-13, or a disease
associated with an elevated TH-2 mediated response comprising administering to a subject in
need thereof a formulation of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic showing an exemplary bispecific anti-IL-4/anti-IL-13 antibody
molecule comprising two light chains and two heavy chains. The two light chains comprise the
moiety N-VL -linker-VL -CL-C, and the two heavy chains comprise the moiety N-
hB-B13 h8D4-8
VH -linker-VH -CH1-CH2-CH3-C. The linker sequence comprises (G4S) or
hB-B13 h8D4-8 2
GGGGSGGGGS (SEQ ID NO: 6).
Figure 2 illustrates the amino acid sequences of an exemplary antibody, i.e., humanized
variable domains of B-B13 anti-IL-13 antibody (SEQ ID NOS: 1 and 2) and humanized variable
domains of 8D4-8 anti-IL-4 antibody (SEQ ID NOS: 3, 4 and 5). Underline indicates amino acid
changes made. Bold indicates the CDR sequences (SEQ ID NOS: 7-21).
Figure 3 is a group of pictures showing particle contamination for assay #P5 (pH-buffer
screening) after shaking stress.
Figure 4 is a graph showing sub-visible particles >1.5µm contamination after several
stresses for assay #P6 (pH-buffer screening).
18169100_1 (GHMatters) P41154NZ00
Figure 5 is a graph showing sub-visible particles >10µm contamination after several
stresses for assay #P6 (pH-buffer screening).
Figure 6 is a graph showing HMW level for assay #P6 (pH-buffer screening) after
thermal stress.
Figure 7 is a graph showing SEC chromatograms of assay #P5 (pH-buffer screening)
after 2 weeks at 45°C.
Figure 8 is a picture of an SDS-PAGE gel of assay #P5 (pH-buffer screening) after 2
weeks at 45°C.
Figure 9 is a picture of an IEF gel after 2 weeks at 45°C for assay #P5 and 6 (pH-buffer
screening).
Figure 10 is a graph showing HMW level after stress program on assay #P13 (salt effect).
Figure 11 shows pictures of binocular images of assay #P12 (surfactant) after mechanical
stress.
Figure 12 is a graph showing HMW monitoring for assay #P12 (surfactant) while stored
6 weeks at 5°C.
Figure 13 is a graph showing HMW monitoring for assay #P12 (additive) while stored 6
weeks at 5°C.
Figure 14 is a graph showing HMW monitoring for assay #P20-FDS (additive) while
stored 4 weeks at 5°C.
Figure 15 is a graph showing HMW monitoring for assay #P21 (additive) while stored 2
weeks at 5°C.
Figure 16 is a graph of the inverse of the monomer content in function of time comparing
1% proline v. 3% proline in the lead formulation.
Figure 17 is a graph following in temperature during a freeze drying process for
formulation #P16-1.
Figure 18 shows pictures of #P18-1 cake in a 15 mL molded glass vial.
Figure 19 is a graph showing HMW level for assay #P14 (additive) after lyophilisation
process.
Figure 20 is a graph showing HMW level for assay #P20 (additive) after lyophilisation.
Figure 21 is a graph showing HMW level (a) and pictures (b) after a freeze/thaw cycle on
non formulated DS (assay #9).
18169100_1 (GHMatters) P41154NZ00
Figure 22 is a graph showing HMW level for assay #P14 (additive) after reconstitution.
Figure 23 is a graph showing HMW level for assay #P20 (additive) after reconstitution.
Figure 24 is a graph showing HMW level for assay #P17 (additive) after cake storage and
reconstitution.
Figure 25 is a graph showing HMW level for assay #P20 (additive) after cake storage and
reconstitution.
Figure 26 is a graph showing DSC results for the first screening (assays #H04-150 to 172
– pH – buffer screening).
Figure 27 shows pictures of a visual aspect of Histidine and Succinate formulations
(assays #P-H04-144 and 148, #H04-150 A1 to A6).
Figure 28 are graphs showing HMW evolutions for buffer screening at 5°C (assays
#H04-150 B1) and RT (assays #H04-163 A1, B1, B2 and H04-172 A1, A2) by SEC.
Figure 29 is a graph showing DSC results for pH screening on Phosphate/Tris buffer
(assays #H04-187).
Figure 30 is a graph showing HMW evolutions for pH screening on Phosphate/Tris
buffer by SEC (assays #H04-187).
Figure 31 is a graph showing DSC results for buffer concentration screening (assays
#H04-185).
Figure 32 are graphs showing HMW evolutions with buffer concentration at RT by SEC
(assays #H04-185).
Figure 33 is a graph showing HMW evolutions for NaCl at RT by SEC (assays #H04-
185).
Figure 34 is a chart showing HMW evolutions for Glycine vs Sucrose at RT by SEC
(assays #H04-185).
DETAILED DESCRIPTION
This invention is not limited to the particular methodology, protocols, cell lines, vectors,
or reagents described herein because they may vary without departing from the spirit and scope
of the invention. Further, the terminology used herein is for the purpose of exemplifying
particular embodiments only and is not intended to limit the scope of the present invention. Any
18169100_1 (GHMatters) P41154NZ00
method and material similar or equivalent to those described herein can be used in the practice of
the present invention and only exemplary methods, devices, and materials are described herein.
All patents and publications mentioned herein are incorporated herein in entirety by
reference for the purpose of describing and disclosing the proteins, enzymes, vectors, host cells
and methodologies reported therein that might be used with and in the present invention.
However, nothing herein is to be construed as an admission that the invention is not entitled to
antedate such disclosure by virtue of prior invention.
A. Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as is commonly understood by one of ordinary skill in the art.
It is noted here that as used in this specification and the appended claims, the singular
forms "a", "an", and "the" also include plural reference, unless the context clearly dictates
otherwise.
The term "about" or "approximately" means within 10%, and more preferably within 5%
(or 1% or less) of a given value or range.
The terms "administer" or "administration" refers to the act of injecting or otherwise
physically delivering a substance as it exists outside the body (e.g., a formulation of the
invention) into a patient, such as by mucosal, intradermal, intravenous, subcutaneous,
intramuscular delivery and/or any other method of physical delivery described herein or known
in the art. When a disease, or a symptom thereof, is being treated, administration of the
substance typically occurs after the onset of the disease or symptoms thereof. When a disease or
its symptoms are being prevented, administration of the substance typically occurs before the
onset of the disease or symptoms thereof.
In the context of a polypeptide, the term "analog" refers to a polypeptide that possesses a
similar or identical function as an anti-IL-4/anti-IL-13 bispecific polypeptide, a fragment of an
anti-IL-4/anti-IL-13 bispecific polypeptide, an anti-IL-4/anti-IL-13 bispecific epitope, or an anti-
IL-4/anti-IL-13 bispecific antibody, but does not necessarily comprise a similar or identical
amino acid sequence of an anti-IL-4/anti-IL-13 bispecific polypeptide, a fragment of an anti-IL-
4/anti-IL-13 bispecific polypeptide, an anti-IL-4/anti-IL-13 bispecific epitope, or an anti-IL-
4/anti-IL-13 bispecific antibody, or possess a similar or identical structure of an anti-IL-4/anti-
18169100_1 (GHMatters) P41154NZ00
IL-13 bispecific polypeptide, a fragment of an anti-IL-4/anti-IL-13 bispecific polypeptide, an
anti-IL-4/anti-IL-13 bispecific epitope,or an anti-IL-4/anti-IL-13 bispecific antibody. A
polypeptide that has a similar amino acid sequence refers to a polypeptide that satisfies at least
one of the following: (a) a polypeptide having an amino acid sequence that is at least 30%, at
least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at
least 70%, at least 75%, at least 80%, at least 85%, and preferably at least 90%, more preferably
at least 95%, or most preferably at least 99% identical to the amino acid sequence of an anti-IL-
4/anti-IL-13 bispecific polypeptide (e.g., SEQ ID NOs: 1-5), a fragment of an anti-IL-4/anti-IL-
13 bispecific polypeptide, an anti-IL-4/anti-IL-13 bispecific epitope, or an anti-IL-4/anti-IL-13
bispecific antibody described herein; (b) a polypeptide encoded by a nucleotide sequence that
hybridizes under stringent conditions to a nucleotide sequence encoding an anti-IL-4/anti-IL-13
bispecific polypeptide, a fragment of an anti-IL-4/anti-IL-13 bispecific polypeptide, an anti-IL-
4/anti-IL-13 bispecific epitope, or an anti-IL-4/anti-IL-13 bispecific antibody (or VH or VL
region thereof) described herein of at least 5 amino acid residues, at least 10 amino acid residues,
at least 15 amino acid residues, at least 20 amino acid residues, at least 25 amino acid residues, at
least 40 amino acid residues, at least 50 amino acid residues, at least 60 amino residues, at least
70 amino acid residues, at least 80 amino acid residues, at least 90 amino acid residues, at least
100 amino acid residues, at least 125 amino acid residues, or at least 150 amino acid residues
(see, e.g., Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y.; Maniatis et al. (1982) Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.); and (c) a polypeptide
encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at
least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at
least 85%, and preferably at least 90%, more preferably at least 95%, or most preferably at least
99% identical to the nucleotide sequence encoding an anti-IL-4/anti-IL-13 bispecific
polypeptide, a fragment of an anti-IL-4/anti-IL-13 bispecific polypeptide, an anti-IL-4/anti-IL-13
bispecific epitope, or an anti-IL-4/anti-IL-13 bispecific antibody (or VH or VL region thereof)
described herein. A polypeptide with similar structure to an anti-IL-4/anti-IL-13 bispecific
antibody polypeptide, a fragment of an anti-IL-4/anti-IL-13 bispecific polypeptide, an anti-IL-
4/anti-IL-13 bispecific epitope, or an anti-IL-4/anti-IL-13 bispecific antibody refers to a
polypeptide that has a similar secondary, tertiary or quaternary structure of an anti-IL-4/anti-IL-
18169100_1 (GHMatters) P41154NZ00
13 bispecific polypeptide, a fragment of an anti-IL-4/anti-IL-13 bispecific polypeptide, an anti-
IL-4/anti-IL-13 bispecific epitope, or an anti-IL-4/anti-IL-13 bispecific antibody. The structure
of a polypeptide can determined by methods known to those skilled in the art, including but not
limited to, X-ray crystallography, nuclear magnetic resonance, and crystallographic electron
microscopy.
To determine the percent identity of two amino acid sequences or of two nucleic acid
sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be
introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment
with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at
corresponding amino acid positions or nucleotide positions are then compared. When a position
in the first sequence is occupied by the same amino acid residue or nucleotide as the
corresponding position in the second sequence, then the molecules are identical at that position.
The percent identity between the two sequences is a function of the number of identical positions
shared by the sequences (i.e., % identity=number of identical overlapping positions/total number
of positions X 100%). In one embodiment, the two sequences are the same length.
The determination of percent identity between two sequences (e.g., amino acid sequences
or nucleic acid sequences) can also be accomplished using a mathematical algorithm. A
preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two
sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2264
2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873 5877.
Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al.,
1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the NBLAST
nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide
sequences homologous to nucleic acid molecules of interest. BLAST protein searches can be
performed with the XBLAST program parameters set, e.g., to score 50, wordlength=3 to obtain
amino acid sequences homologous to a protein molecule of interest. To obtain gapped
alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et
al., 1997, Nucleic Acids Res. 25:3389 3402. Alternatively, PSI BLAST can be used to perform
an iterated search which detects distant relationships between molecules (Id.). When utilizing
BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective
programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., National Center for
18169100_1 (GHMatters) P41154NZ00
Biotechnology Information (NCBI) on the worldwide web at ncbi dot nlm dot nih dot gov).
Another preferred, non limiting example of a mathematical algorithm utilized for the comparison
of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11 17. Such an algorithm is
incorporated in the ALIGN program (version 2.0), which is part of the GCG sequence alignment
software package. When utilizing the ALIGN program for comparing amino acid sequences, a
PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
The percent identity between two sequences can be determined using techniques similar
to those described above, with or without allowing gaps. In calculating percent identity,
typically only exact matches are counted.
An "antagonist" or “inhibitor” refers to a molecule capable of inhibiting one or more
biological activities of a target molecule, such as signaling by IL-4 and/or IL-13. Antagonists
may interfere with the binding of a receptor to a ligand and vice versa, by incapacitating or
killing cells activated by a ligand, and/or by interfering with receptor or ligand activation (e.g.,
tyrosine kinase activation) or signal transduction after ligand binding to a receptor. The
antagonist may completely block receptor-ligand interactions or may substantially reduce such
interactions. In certain embodiments of the invention, the anti-IL-4/anti-IL-13 bispecific
antibodies are humanized, antagonistic anti-IL-4/anti-IL-13 bispecific antibodies, preferably
humanized, monoclonal, antagonistic anti-IL-4/anti-IL-13 bispecific antibodies.
The terms "antibody", "immunoglobulin", or "Ig" may be used interchangeably herein.
The term antibody includes, but is not limited to, synthetic antibodies, monoclonal antibodies,
recombinantly produced antibodies, multispecific antibodies (including bi-specific antibodies),
human antibodies, humanized antibodies, chimeric antibodies, intrabodies, single-chain Fvs
(scFv) (e.g., including monospecific, bispecific, etc.), camelized antibodies, Fab fragments,
F(ab') fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies, and epitope-
binding fragments of any of the above. In particular, antibodies include immunoglobulin
molecules and immunologically active portions of immunoglobulin molecules, i.e., antigen
binding domains or molecules that contain an antigen-binding site that specifically binds to an
IL-4 or IL-13 antigen (e.g., one or more complementarity determining regions (CDRs) of an anti-
IL-4/anti-IL-13 bispecific antibody). The anti-IL-4/anti-IL-13 bispecific antibodies can be of
any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1
and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. In preferred
18169100_1 (GHMatters) P41154NZ00
embodiments, the anti-IL-4/anti-IL-13 bispecific antibodies are humanized, such as humanized
monoclonal anti-IL-4/anti-IL-13 bispecific antibodies. In certain embodiments, the anti-IL-
4/anti-IL-13 bispecific antibodies are IgG antibodies, human IgG4 antibodies.
The term "antigen" refers to a molecule or a portion of a molecule capable of being
bound by the antibodies of the present invention. An antigen can have one or more than one
epitope. Examples of antigens recognized by the antibodies of the present invention include, but
are not limited to, serum proteins, e.g., cytokines such as IL-4, IL5, IL9 and IL-13, bioactive
peptides, cell surface molecules, e.g., receptors, transporters, ion-channels, viral and bacterial
proteins.
The term “antigen binding site” refers to the part of the antibody that comprises the area
that specifically binds to and is complementary to part or all of an antigen. Where an antigen is
large, an antibody may only bind to a particular part of the antigen, which part is termed on
epitope. An antigen binding domain may be provided by one or more antibody variable
domains. Preferably, an antigen binding domain is made of the association of an antibody light
chain variable domain (VL) and an antibody heavy chain variable domain (VH).
The term "binding agent" means any molecule, such as an antibody, a siRNA, a nucleic
acid, an aptamer, a protein, or a small molecule organic compound, that binds or specifically
binds to IL-4 and/or IL-13, or a variant or a fragment thereof.
The terms “bispecific antibody” or “bispecific antibodies (BsAbs)” refers to molecules
that combine the antigen-binding sites of two antibodies within a single molecule. Thus, a
bispecific antibody is able to bind two different antigens simultaneously. Besides applications
for diagnostic purposes, BsAbs pave the way for new therapeutic applications by redirecting
potent effector systems to diseased areas or by increasing neutralizing or stimulating activities of
antibodies. Bispecific antibodies can be monoclonal, but are preferably human or humanized.
Methods for making bispecific antibodies are well known in the art.
The term "by-product" includes undesired products, which detract or diminish the
proportion of therapeutic/prophylactic binding agent, such as an antibody, in a given
formulation. For example, typical by-products include aggregates of the antibody, fragments of
the antibody, e.g. produced by degradation of the antibody by deamidation or hydrolysis, or
mixtures thereof. Typically, aggregates are complexes that have a molecular weight greater than
the monomer antibody. Antibody degradation products may include, for example, fragments of
18169100_1 (GHMatters) P41154NZ00
the antibody, for example, brought about by deamidation or hydrolysis. Typically, degradation
products are complexes that have a molecular weight less than the monomer antibody. In the
case of an IgG antibody, such degradation products are less than about 150 kD.
The terms "composition" and "formulation" are intended to encompass a product
containing the specified ingredients (e.g., an anti-IL-4/anti-IL-13 bispecific antibody) in,
optionally, the specified amounts, as well as any product which results, directly or indirectly,
from the combination of the specified ingredients in, optionally, the specified amounts.
The terms "constant region" or "constant domain" refer to a carboxy terminal portion of
the light and heavy chain which is not directly involved in binding of the antibody to antigen but
exhibits various effector functions, such as interaction with the Fc receptor. The terms refer to
the portion of an immunoglobulin molecule having a more conserved amino acid sequence
relative to the other portion of the immunoglobulin, the variable domain, which contains the
antigen binding site. The constant domain contains the CH1, CH2 and CH3 domains of the
heavy chain and the CHL domain of the light chain.
The term "disorder" refers to any condition that would benefit from treatment with the
formulation of the present invention. This includes chronic and acute disorders or diseases
including those pathological conditions which predispose the mammal, and in particular humans,
to the disorder in question. Non-limiting examples of disorders to be treated herein include
cancers, inflammation, autoimmune diseases, infections, cardiovascular diseases, respiratory
diseases, neurological diseases and metabolic diseases.
The term "epitope" refers to a localized region on the surface of an antigen, such as an
IL-4 or IL-13 polypeptide or IL-4 or IL-13 polypeptide fragment, that is capable of being bound
to one or more antigen binding regions of a binding agent, such as an antibody, and that has
antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a
human, that is capable of eliciting an immune response. An epitope having immunogenic
activity is a portion of a polypeptide that elicits an antibody response in an animal. An epitope
having antigenic activity is a portion of a polypeptide to which an antibody specifically binds, as
determined by any method well known in the art, for example, such as an immunoassay.
Antigenic epitopes need not necessarily be immunogenic. Epitopes usually consist of chemically
active surface groupings of molecules, such as amino acids or sugar side chains, and have
specific three dimensional structural characteristics, as well as specific charge characteristics. A
18169100_1 (GHMatters) P41154NZ00
region of a polypeptide contributing to an epitope may be contiguous amino acids of the
polypeptide or the epitope may come together from two or more non-contiguous regions of the
polypeptide. The epitope may or may not be a three-dimensional surface feature of the antigen.
In certain embodiments, an IL-4 or IL-13 epitope is a three-dimensional surface feature of an IL-
4 or IL-13 polypeptide. In other embodiments, an IL-4 or IL-13 epitope is a linear feature of an
IL-4 or IL-13 polypeptide. Anti-IL-4/anti-IL-13 bispecific antibodies may specifically bind to an
epitope of the denatured form of IL-4 or IL-13, an epitope of the native form of IL-4 or IL-13, or
both the denatured form and the native form of IL-4 or IL-13.
The term "excipients" refers to inert substances that are commonly used as a diluent,
vehicle, preservative, binder, stabilizing agent, etc. for drugs and includes, but is not limited to,
proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine,
arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, caprylate,
etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g., sucrose,
maltose, trehalose, etc.) and polyols (e.g., mannitol, sorbitol, etc.). See, also, Remington's
Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pa., which is hereby incorporated
by reference in its entirety.
In the context of a peptide or polypeptide, the term "fragment" refers to a peptide or
polypeptide that comprises less than the full length amino acid sequence. Such a fragment may
arise, for example, from a truncation at the amino terminus, a truncation at the carboxy terminus,
and/or an internal deletion of a residue(s) from the amino acid sequence. Fragments may, for
example, result from alternative RNA splicing or from in vivo protease activity. In certain
embodiments, hIL-4 or hIL-13 fragments include polypeptides comprising an amino acid
sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid
residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues,
at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50
contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous
amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino
acid residues, at least contiguous 100 amino acid residues, at least 125 contiguous amino acid
residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid
residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid
18169100_1 (GHMatters) P41154NZ00
residues of the amino acid sequence of an IL-4 or IL-13 polypeptide or an antibody that
specifically binds to an IL-4 or IL-13 polypeptide.
The phrases and terms "functional fragment, variant, derivative or analog" and the like, as
well as forms thereof, of an antibody or antigen is a compound or molecule having qualitative
biological activity in common with a full-length antibody or antigen of interest. For example, a
functional fragment or analog of an anti-IL-4 antibody is one which can bind to an IL-4 molecule
or one which can prevent or substantially reduce the ability of a ligand, or an agonistic or
antagonistic antibody, to bind to IL-4.
The term "heavy chain" when used in reference to an antibody refers to five distinct
types, called alpha (α), delta (Δ), epsilon (ε), gamma (γ), and mu (μ), based on the amino acid
sequence of the heavy chain constant domain. These distinct types of heavy chains are well
known in the art and give rise to five classes of antibodies, IgA, IgD, IgE, IgG, and IgM,
respectively, including four subclasses of IgG, namely IgG1, IgG1, IgG3, and IgG4. Preferably
the heavy chain is a human heavy chain.
The term "hinge" or "hinge region" refers to the flexible polypeptide comprising the
amino acids between the first and second constant domains of an antibody.
"Humanized" forms of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such as F , F , F , F or
v ab ab' (ab')2
other target-binding subsequences of antibodies) which contain sequences derived from non-
human immunoglobulin, as compared to a human antibody. In general, the humanized antibody
will comprise substantially all of one, and typically two, variable domains, in which all or
substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all
or substantially all of the FR regions are those of a human immunoglobulin template sequence.
The humanized antibody may also comprise at least a portion of an immunoglobulin constant
region (F ), typically that of the human immunoglobulin template chosen. In general, the goal is
to have an antibody molecule that is minimally immunogenic in a human. Thus, it is possible
that one or more amino acids in one or more CDRs also can be changed to one that is less
immunogenic to a human host, without substantially minimizing the specific binding function of
the one or more CDRs to IL-4 and/or IL-13. Alternatively, the FR can be non-human but those
amino acids most immunogenic are replaced with ones less immunogenic. Nevertheless, CDR
grafting, as discussed above, is not the only way to obtain a humanized antibody. For example,
18169100_1 (GHMatters) P41154NZ00
modifying just the CDR regions may be insufficient as it is not uncommon for framework
residues to have a role in determining the three-dimensional structure of the CDR loops and the
overall affinity of the antibody for its ligand. Hence, any means can be practiced so that the non-
human parent antibody molecule is modified to be one that is less immunogenic to a human, and
global sequence identity with a human antibody is not always a necessity. So, humanization also
can be achieved, for example, by the mere substitution of just a few residues, particularly those
which are exposed on the antibody molecule and not buried within the molecule, and hence, not
readily accessible to the host immune system. See, for example, Studnicka et al., Prot Eng
7(6)805-814, 1994; Mol Imm 44:1986-1988, 2007; Sims et al., J Immunol 151:2296 (1993);
Chothia et al., J Mol Biol 196:901 (1987); Carter et al., Proc Natl Acad Sci USA 89:4285 (1992);
Presta et al., J Immunol 151:2623 (1993), and U.S. Pat. No. 5,869,619.
Alternatively, antibodies can be humanized by other techniques including CDR grafting (EPO 0
239 400; WO 91/09967; and U.S. Pat. Nos. 5,530,101 and 5,585,089), veneering or resurfacing
(EPO 0 592 106; EPO 0 519 596; Padlan, 1991, Molec Imm 28(4/5):489-498; Studnicka et al.,
1994, Prot Eng 7(6):805-814; and Roguska et al., 1994, PNAS 91:969-973) and chain shuffling
(U.S. Pat. No. 5,565,332). Human antibodies can be made by a variety of methods known in the
art including, but not limited to, phage display methods, see U.S. Pat. Nos. 4,444,887, 4,716,111,
,545,806 and 5,814,318; and WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO
96/34096, WO 96/33735 and WO 91/10741, using transgenic animals, such as rodents, using
chimeric cells and so on.
“Interleukin-4” (IL-4) relates to the naturally occurring, or endogenous mammalian IL-4
proteins and to proteins having an amino acid sequence which is the same as that of a naturally
occurring or endogenous corresponding mammalian IL-4 protein {e.g., recombinant proteins,
synthetic proteins (i.e., produced using the methods of synthetic organic chemistry)).
Accordingly, as defined herein, the term includes mature IL-4 protein, polymorphic or allelic
variants, and other isoforms of an IL-4 and modified or unmodified forms of the foregoing (e.g.,
lipidated, glycosylated). Naturally occurring or endogenous IL-4 includes wild type proteins
such as mature IL-4, polymorphic or allelic variants and other isoforms and mutant forms which
occur naturally in mammals (e.g., humans, non-human primates). Such proteins can be
recovered or isolated from a source which naturally produces IL-4, for example. These proteins
and proteins having the same amino acid sequence as a naturally occurring or endogenous
18169100_1 (GHMatters) P41154NZ00
corresponding IL-4, are referred to by the name of the corresponding mammal. For example,
where the corresponding mammal is a human, the protein is designated as a human IL-4. Several
mutant IL-4 proteins are known in the art, such as those disclosed in WO 03/038041.
"Interleukin-13" (IL-13) refers to naturally occurring or endogenous mammalian IL-13
proteins and to proteins having an amino acid sequence which is the same as that of a naturally
occurring or endogenous corresponding mammalian IL-13 protein (e.g., recombinant proteins,
synthetic proteins (i.e., produced using the methods of synthetic organic chemistry)).
Accordingly, as defined herein, the term includes mature IL-13 protein, polymorphic or allelic
variants, and other isoforms of IL-13 (e.g., produced by alternative splicing or other cellular
processes), and modified or unmodified forms of the foregoing (e.g., Hpidated, glycosylated).
Naturally occurring or endogenous IL-13 include wild type proteins such as mature IL-13,
polymorphic or allelic variants and other isoforms and mutant forms which occur naturally in
mammals (e.g., humans, non- human primates). For example, as used herein IL-13 encompasses
the human IL-13 variant in which Arg at position 110 of mature human IL-13 is replaced with
Gin (position 110 of mature IL-13 corresponds to position 130 of the precursor protein) which is
associated with asthma (atopic and nonatopic asthma) and other variants of IL-13. (Heinzmann
el al, Hum MoI Genet. 9:549-559 (2000).) Such proteins can be recovered or isolated from a
source which naturally produces IL-13, for example. These proteins and proteins having the
same amino acid sequence as a naturally occurring or endogenous corresponding IL-13 are
referred to by the name of the corresponding mammal. For example, where the corresponding
mammal is a human, the protein is designated as a human IL-13. Several mutant IL-13 proteins
are known in the art, such as those disclosed in WO 03/035847.
An "isolated" or "purified" binding agent, such as an antibody, is substantially free of
cellular material or other contaminating proteins from the cell or tissue source from which the
binding agent is derived, or substantially free of chemical precursors or other chemicals when
chemically synthesized. For example, the language "substantially free of cellular material"
includes preparations of an antibody in which the antibody is separated from cellular components
of the cells from which it is isolated or recombinantly produced. Thus, an antibody that is
substantially free of cellular material includes preparations of antibody having less than about
%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a
"contaminating protein"). When the antibody is recombinantly produced, it is also preferably
18169100_1 (GHMatters) P41154NZ00
substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%,
or 5% of the volume of the protein preparation. When the antibody is produced by chemical
synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is
separated from chemical precursors or other chemicals that are involved in the synthesis of the
protein. Accordingly, such preparations of the antibody have less than about 30%, 20%, 10%,
% (by dry weight) of chemical precursors or compounds other than the antibody of interest. In
a preferred embodiment, anti-IL-4/anti-IL-13 bispecific antibodies are isolated or purified.
The term "Kabat numbering," and like terms are recognized in the art and refer to a
system of numbering amino acid residues that are more variable (i.e. hypervariable) than other
amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen
binding portion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and, Kabat et al.
(1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of
Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable
region, the hypervariable region typically ranges from amino acid positions 31 to 35 for CDR1,
amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the
light chain variable region, the hypervariable region typically ranges from amino acid positions
24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97
for CDR3.
The term "light chain" when used in reference to an antibody refers to two distinct types,
called kappa (κ) of lambda (λ) based on the amino acid sequence of the constant domains. Light
chain amino acid sequences are well known in the art. In preferred embodiments, the light chain
is a human light chain.
The term “linker” refers to a molecule that connects the antigen binding domains of the
antibody. The linker may be any kind of linker molecule. Preferably, the linker is a polypeptide.
The linkers may be equal or differ from each other between and within the heavy chain
polypeptide and the light chain polypeptide. Furthermore, the linker may have a length of 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. A preferred peptide
linker unit for the heavy chain domains as for the light chain domains is (G4S) , i.e.,
GGGGSGGGGS (SEQ ID NO: 6). The numbers of linker units of the heavy chain and of the
light chain may be equal (symmetrical order) or differ from each other (asymmetrical order). A
peptide linker is preferably long enough to provide an adequate degree of flexibility to prevent
18169100_1 (GHMatters) P41154NZ00
the antigen binding moieties from interfering with each others activity, for example by steric
hindrance, to allow for proper protein folding and, if necessary, to allow the antibody molecules
to interact with two or more, possibly widely spaced, receptors on the same cell; yet it is
preferably short enough to allow the antibody moieties to remain stable in the cell. Therefore,
the length, composition and/or conformation of the peptide linkers can readily be selected by one
skilled in the art in order to optimize the desired properties of the polyvalent antibody.
The terms “low salt” and “low salt concentration” mean a relatively low salt
concentration of 15 mM or less, including a salt concentration of 0 or no salt. The salt
concentration is determined by the amount of salts and buffers in the formulation. It is
preferable that the buffering system is present in the formulations in a low concentration, i.e.,
about 15 mM or less, in order to lower the ionic strength of the formulations. Alternatively,
some preferred embodiments contain no salt and no buffer. It is also preferable that no
additional salts, such as NaCl are added to the formulations, in order to keep the ionic strength of
the formulations as low as possible.
The terms "manage", "managing", and "management" refer to the beneficial effects that a
subject derives from a therapy (e.g., a prophylactic or therapeutic agent), which does not result in
a cure of the infection. In certain embodiments, a subject is administered one or more therapies
(e.g., prophylactic or therapeutic agents, such as a formulation of the invention) to "manage" an
IL-4 or ILmediated disease (e.g., cancers, inflammation, autoimmune diseases, infections,
cardiovascular diseases, respiratory diseases, neurological diseases, and metabolic diseases), one
or more symptoms thereof, so as to prevent the progression or worsening of the disease.
The term "monoclonal antibody" refers to an antibody obtained from a population of
homogenous or substantially homogeneous antibodies, and each monoclonal antibody will
typically recognize a single epitope on the antigen. In preferred embodiments, a "monoclonal
antibody" is an antibody produced by a single hybridoma or other cell. The term "monoclonal"
is not limited to any particular method for making the antibody. For example, monoclonal
antibodies may be made by the hybridoma method as described in Kohler et al.; Nature, 256:495
(1975) or may be isolated from phage libraries. Other methods for the preparation of clonal cell
lines and of monoclonal antibodies expressed thereby are well known in the art (see, for
example, Chapter 11 in: Short Protocols in Molecular Biology, (2002) 5th Ed.; Ausubel et al.,
eds., John Wiley and Sons, New York).
18169100_1 (GHMatters) P41154NZ00
The term "pharmaceutical composition" as used in the present invention refers to
formulations of various preparations. The formulations containing therapeutically effective
amounts of the antibodies are sterile liquid solutions, liquid suspensions or lyophilized versions
and optionally contain stabilizers or excipients.
The term "pharmaceutically acceptable" means being approved by a regulatory agency of
the Federal or a state government, or listed in the U.S. Pharmacopeia, European Pharmacopeia or
other generally recognized Pharmacopeia for use in animals, and more particularly in humans.
By "pharmaceutically acceptable excipient" is meant any inert substance that is combined
with an active molecule, such as a monoclonal antibody, for preparing an agreeable or
convenient dosage form. The "pharmaceutically acceptable excipient" is an excipient that is
non-toxic to recipients at the dosages and concentrations employed, and is compatible with other
ingredients of the formulation comprising the monoclonal antibody.
The terms "prevent", "preventing", and "prevention" refer to the total or partial inhibition
of the development, recurrence, onset or spread of an IL-4 or IL-13 -mediated disease and/or
symptom related thereto, resulting from the administration of a therapy or combination of
therapies provided herein (e.g., a combination of prophylactic or therapeutic agents, such as a
formulation of the invention).
The term "prophylactic agent" refers to any agent that can totally or partially inhibit the
development, recurrence, onset or spread of an IL-4 or IL-13 -mediated disease and/or symptom
related thereto in a subject. In certain embodiments, the term "prophylactic agent" refers to a
formulation of the invention. In certain other embodiments, the term "prophylactic agent" refers
to an agent other than a formulation of the invention. Preferably, a prophylactic agent is an agent
that is known to be useful to or has been or is currently being used to prevent an IL-4 or IL-13 -
mediated disease and/or a symptom related thereto, or impede the onset, development,
progression and/or severity of an IL-4 or IL-13 -mediated disease and/or a symptom related
thereto. In specific embodiments, the prophylactic agent is a humanized anti-IL-4/anti-IL-13
bispecific antibody.
The phrase "recombinant antibody" includes antibodies that are prepared, expressed,
created, or isolated by recombinant means, such as antibodies expressed using a recombinant
expression vector transfected into a host cell, antibodies isolated from a recombinant,
combinatorial human antibody library, antibodies isolated from an animal (e.g., a mouse or cow)
18169100_1 (GHMatters) P41154NZ00
that is transgenic and/or transchromosomal for human immunoglobulin genes (see, e.g., Taylor,
L. D. et al. (1992) Nucl. Acids Res. 20:6287-6295) or antibodies prepared, expressed, created, or
isolated by any other means that involves splicing of human immunoglobulin gene sequences to
other DNA sequences. Such recombinant antibodies can have variable and constant regions
derived from immunoglobulin sequences (See Kabat, E. A. et al. (1991) Sequences of Proteins of
Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH
Publication No. 91-3242). In certain embodiments, however, such recombinant antibodies are
subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used,
in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the
recombinant antibodies are sequences that, while derived from and related to germline VH and
VL sequences, may not naturally exist within the antibody germline repertoire in vivo.
The term "saccharide" refers to a class of molecules that are derivatives of polyhydric
alcohols. Saccharides are commonly referred to as carbohydrates and may contain different
amounts of sugar (saccharide) units, e.g., monosaccharides, disaccharides and polysaccharides.
The terms "specifically binds" or "specifically binding" mean specifically binding to an
antigen or a fragment thereof and not specifically binding to other antigens. For example, an
antibody that specifically binds to an antigen may bind to other peptides or polypeptides with
lower affinity, as determined by, e.g., radioimmunoassays (RIA), enzyme-linked immunosorbent
assays (ELISA), BIACORE, or other assays known in the art. Antibodies or variants or
fragments thereof that specifically bind to an antigen may be cross-reactive with related antigens.
Preferably, antibodies or variants or fragments thereof that specifically bind to an antigen do not
cross-react with other antigens. An antibody or a variant or a fragment thereof that specifically
binds to an IL-4 and/or IL-13 antigen can be identified, for example, by immunoassays, BIAcore,
or other techniques known to those of skill in the art. Typically a specific or selective reaction
will be at least twice background signal or noise, and more typically more than 10 times
background. See, e.g., Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press,
New York at pages 332-336 for a discussion regarding antibody specificity.
A "stable" or "stabilized" formulation is one in which the binding agent, such as an
antibody, therein essentially retains its physical stability, identity, integrity, and/or chemical
stability, identity, integrity, and/or biological activity upon storage. Various analytical
techniques for measuring protein stability are available in the art and are reviewed in Peptide and
18169100_1 (GHMatters) P41154NZ00
Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N.Y., Pubs.
(1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993), for example. Stability can be
measured at a selected temperature and other storage conditions for a selected time period. The
stability may be determined by at least one of the methods selected from the group consisting of
visual inspection, SDS-PAGE, IEF, HPSEC, RFFIT, and kappa/lambda ELISA. For example, an
antibody "retains its physical stability" in a pharmaceutical formulation, if it shows no signs of
aggregation, precipitation, and/or denaturation upon visual examination of color and/or clarity, or
as measured by UV light scattering, SDS-PAGE, or by (high pressure) size exclusion
chromatography (HPSEC). Preferably, when using the formulations of the invention, 5% or less,
typically 4% or less, preferably 3% or less, more preferably 2% or less, and particularly 1% or
less of the antibodies forms aggregates, as measured by HPSEC or any other suitable method for
measuring aggregation formation. For example, an antibody is considered stable in a particular
formulation if the antibody monomer has a purity of about 90%, preferably about 95%, in
particular about 98% after a certain predetermined period of time under certain storage
conditions in a particular formulation. Chemical stability can be assessed by detecting and
quantifying chemically altered forms of the protein. Chemical alteration may involve size
modification (e.g., clipping), which can be evaluated using (HP)SEC, SDS-PAGE, and/or
matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS),
for example. Other types of chemical alteration include charge alteration (e.g., occurring as a
result of deamidation), which can be evaluated by ion-exchange chromatography, for example.
An antibody "retains its biological activity" in a pharmaceutical formulation at a given time, if
the biological activity of the antibody at a given time is at least about 90% (within the errors of
the assay) of the biological activity exhibited at the time the pharmaceutical formulation was
prepared, as determined in an antigen binding assay or virus neutralizing assay, for example.
The terms "subject" and "patient" are used interchangeably. As used herein, a subject is
preferably a mammal, such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a
primate (e.g., monkey and human), most preferably a human. In one embodiment, the subject is
a mammal, preferably a human, having an IL-4 and/or IL-13 -mediated disease. In another
embodiment, the subject is a mammal, preferably a human, at risk of developing an IL-4 and/or
IL-13 -mediated disease.
18169100_1 (GHMatters) P41154NZ00
The phrase "substantially identical" with respect to an antibody chain polypeptide
sequence may be construed as an antibody chain exhibiting at least 70%, 80%, 90%, 95% or
more sequence identity to the reference polypeptide sequence. The term with respect to a nucleic
acid sequence may be construed as a sequence of nucleotides exhibiting at least about 85%, 90%,
95%, or 97% or more sequence identity to the reference nucleic acid sequence.
"Substitutional" variants are those that have at least one amino acid residue in a native
sequence removed and replaced with a different amino acid inserted in its place at the same
position. The substitutions may be single, where only one amino acid in the molecule is
substituted, or may be multiple, where two or more amino acids are substituted in the same
molecule. The plural substitutions may be at consecutive sites. Also, one amino acid can be
replaced with plural residues, in which case such a variant comprises both a substitution and an
insertion. "Insertional" variants are those with one or more amino acids inserted immediately
adjacent to an amino acid at a particular position in a native sequence. Immediately adjacent to
an amino acid means connected to either the α-carboxyl or α-amino functional group of the
amino acid. "Deletional" variants are those with one or more amino acids in the native amino
acid sequence removed. Ordinarily, deletional variants will have one or two amino acids deleted
in a particular region of the molecule.
The term "therapeutically effective amount" refers to the amount of a therapy (e.g., a
formulation of the invention) that is sufficient to reduce and/or ameliorate the severity and/or
duration of a given disease and/or a symptom related thereto. This term also encompasses an
amount necessary for the reduction or amelioration of the advancement or progression of a given
disease, reduction or amelioration of the recurrence, development or onset of a given disease,
and/or to improve or enhance the prophylactic or therapeutic effect(s) of another therapy (e.g., a
therapy other than a formulation of the invention). In some embodiments, the therapeutically
effective amount of an antibody of the invention provides a local concentration of between about
and 20 ng/ml, and preferably, between about 10 and 20 ng/ml. In some embodiments,
"therapeutically effective amount" as used herein also refers to the amount of an antibody of the
invention to achieve a specified result (e.g., inhibition of an IL-4 and/or IL-13 cytokine).
The term "therapeutic agent" refers to any agent that can be used in the treatment,
management or amelioration of an IL-4 and/or IL-13 -mediated disease and/or a symptom related
thereto. In certain embodiments, the term "therapeutic agent" refers to a formulation of the
18169100_1 (GHMatters) P41154NZ00
invention. In certain other embodiments, the term "therapeutic agent" refers to an agent other
than a formulation of the invention. Preferably, a therapeutic agent is an agent that is known to
be useful for, or has been or is currently being used for the treatment, management or
amelioration of an IL-4 and/or ILmediated disease or one or more symptoms related thereto.
The term "therapy" refers to any protocol, method, and/or agent that can be used in the
prevention, management, treatment, and/or amelioration of an IL-4 and/or IL-13 -mediated
disease (e.g., cancers, inflammation, autoimmune diseases, infections, cardiovascular diseases,
respiratory diseases, neurological diseases, and metabolic diseases). In certain embodiments, the
terms "therapies" and "therapy" refer to a biological therapy, supportive therapy, and/or other
therapies useful in the prevention, management, treatment, and/or amelioration of an IL-4 and/or
IL-13 -mediated disease known to one of skill in the art, such as medical personnel.
The terms "treat", "treatment", and "treating" refer to the reduction or amelioration of the
progression, severity, and/or duration of an IL-4 and/or IL-13 -mediated disease (e.g., cancers,
inflammation, autoimmune diseases, infections, cardiovascular diseases, respiratory diseases,
neurological diseases, and metabolic diseases) resulting from the administration of one or more
therapies (including, but not limited to, the administration of one or more prophylactic or
therapeutic agents, such as a formulation of the invention).
The terms "variable region" or "variable domain" refer to a portion of the light and heavy
chains, typically about the amino-terminal 120 to 130 amino acids in the heavy chain and about
100 to 110 amino acids in the light chain, which differ extensively in sequence among antibodies
and are used in the binding and specificity of each particular antibody for its particular antigen.
The variability in sequence is concentrated in those regions called complementarity determining
regions (CDRs), while the more highly conserved regions in the variable domain are called
framework regions (FR). The CDRs of the light and heavy chains are primarily responsible for
the interaction of the antibody with antigen. Numbering of amino acid positions is according to
the EU Index, as in Kabat et al. (1991) Sequences of proteins of immunological interest. (U.S.
Department of Health and Human Services, Washington, D.C.) 5 ed. ("Kabat et al."). In
preferred embodiments, the variable region is a human variable region.
B. Formulations and Formulation Components
18169100_1 (GHMatters) P41154NZ00
As stated previously, the formulations of the invention comprise an anti-IL-4/anti-IL-13
bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and
wherein the formulation has a low salt concentration in order to reduce the ionic strength of the
formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar,
and/or a non-ionic stabilizing agent. The formulations of the invention have been found to
provide significant improvements over prior anti-IL-4/anti-IL-13 bispecific antibody
formulations, which often lead to molecular aggregation of the antibody upon increasing the
concentration of the antibody in the formulation, and the formation of visible and sub-visible
particles. In particular, the formulations of the invention exhibit good stability regarding visible
particles, sub-visible particles, low molecular weight proteins, and high molecular weight
proteins.
i. Anti-IL-4/anti-IL-13 Bispecific Antibodies, and variants and fragments thereof
In certain embodiments, the formulations of the invention include an anti-IL-4/anti-IL-13
bispecific antibody. The bispecific antibody binds or specifically binds to IL-4 and/or IL-13, or
variants or fragments thereof. The IL-4 and/or IL-13 molecules may be from any species.
Preferably, the IL-4 and/or IL-13 molecules are from a human. The amino acid sequences and
protein structures of both IL-4 and IL-13 are well known in the art.
In certain exemplary embodiments, the anti-IL-4/anti-IL-13 bispecific antibody is a
humanized antibody, a fully human antibody, or a variant thereof or an antigen-binding fragment
thereof. Preferred anti-IL-4/anti-IL-13 bispecific antibodies prevent binding of IL-4 and IL-13
with their receptors, and inhibit IL-4 and IL-13 biological activity.
In a specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof comprises a light chain variable region (VL) that binds to IL-13 comprising the
amino acid sequence of SEQ ID NO: 1 (Underline indicates amino acid changes made. Bold
indicates the CDRs; CDR1 is SEQ ID NO: 7 RASESVDSYGQSYMH; CDR2 is SEQ ID NO: 8
LASNLES; and CDR3 is SEQ ID NO: 9 QQNAEDSRT).
18169100_1 (GHMatters) P41154NZ00
In a specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof comprises a heavy chain variable region (VH) that binds to IL-13 comprising
the amino acid sequence of SEQ ID NO: 2 (Underline indicates amino acid changes made. Bold
indicates the CDRs; CDR1 is SEQ ID NO: 10 GFSLTDSSIN; CDR2 is SEQ ID NO: 11 DGRID;
and CDR3 is SEQ ID NO: 12 DGYFPYAMDF).
In a specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof comprises a light chain variable region (VL) that binds to IL-4 comprising the
amino acid sequence of SEQ ID NO: 3 (Underline indicates amino acid changes made. Bold
indicates the CDRs; CDR1 is SEQ ID NO: 13 HASQNIDVWLS; CDR2 is SEQ ID NO: 14
KASNLHTG; CDR3 is SEQ ID NO: 15 QQAHSYPFT).
In a specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof comprises a heavy chain variable region (VH) that binds to IL-4 comprising the
amino acid sequence of SEQ ID NO: 4 (Underline indicates amino acid changes made. Bold
indicates the CDRs; CDR 1 is SEQ ID NO: 16 GYSFTSYWIH; CDR2 is SEQ ID NO: 17
IDPSDGETR; and CDR3 is SEQ ID NO: 18 LKEYGNYDSFYFDV).
18169100_1 (GHMatters) P41154NZ00
In another specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody or antigen
binding fragment thereof comprises a heavy chain variable region (VH) that binds to IL-4
comprising the amino acid sequence of SEQ ID NO: 5 (Underline indicates amino acid changes
made. Bold indicates the CDRs; CDR 1 is SEQ ID NO: 19 GYSFTSYWIH; CDR2 is SEQ ID
NO: 20 IDASDGETR; and CDR3 is SEQ ID NO: 21 LKEYGNYDSFYFDV).
In some specific embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or antigen
binding fragment thereof comprises a heavy chain variable region that binds to IL-13 comprising
the amino acid sequence of SEQ ID NO: 2; and a light chain variable region that binds to IL-13
comprising the amino acid sequence of SEQ ID NO: 1.
In other specific embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or antigen
binding fragment thereof comprises a heavy chain variable region that binds to IL-4 comprising
the amino acid sequence of SEQ ID NO: 4; and a light chain variable region that binds to IL-4
comprising the amino acid sequence of SEQ ID NO: 3.
In still other specific embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or
antigen binding fragment thereof comprises a heavy chain variable region that binds to IL-4
comprising the amino acid sequence of SEQ ID NO: 5; and a light chain variable region that
binds to IL-4 comprising the amino acid sequence of SEQ ID NO: 3.
In more specific embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or antigen
binding fragment thereof comprises a heavy chain variable region that binds to both IL-13 and
IL-4 comprising the amino acid sequences of SEQ ID NOs: 2 and 4, or 2 and 5; and a light chain
variable region that binds to both IL-13 and IL-4 comprising the amino acid sequences of SEQ
ID NOs: 1 and 3.
In a most specific embodiment, the anti-IL-4/anti-IL-13 bispecific antibody comprises a
heavy chain variable region that binds to both IL-13 and IL-4 comprising the amino acid
sequences of SEQ ID NOs: 2 and 4; and a light chain variable region that binds to both IL-13
and IL-4 comprising the amino acid sequences of SEQ ID NOs: 1 and 3 (the “Lead Antibody”).
A schematic drawing of an embodiment of the anti-IL-4/anti-IL-13 bispecific antibody is shown
18169100_1 (GHMatters) P41154NZ00
in Figure 1, and exemplary heavy and light chain variable regions are shown in Figure 2. The
molecular weight of the Lead Antibody, as determined by mass spectrometry is 198 kDa. The
isoelectric point of the Lead Antibody, as determined by isoelectric focusing, ranges between 5.8
and 6.2.
In alternative most specific embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or
an antigen binding fragment thereof comprises a light chain of the formula VL1-linker-VL2 and
a heavy chain of the formula VH1-linker-VH2, wherein VL1 and VH1 form an IL-4 antigen
binding domain and VL2 and VH2 form an IL-13 antigen binding domain. In some
embodiments, VL1 comprises the CDR sequences of SEQ ID NO: 1; VH1 comprises the CDR
sequences of SEQ ID NO: 2; VL2 comprises the CDR sequences of SEQ ID NO: 3; and VH2
comprises the CDR sequences of SEQ ID NO: 4 or 5. In alternative embodiments, VL2
comprises the amino acid sequence of SEQ ID NO: 1; VH2 comprises the amino acid sequence
of SEQ ID NO: 2; VL1comprises the amino acid sequence of SEQ ID NO: 3; and VH1comprises
the amino acid sequence of SEQ ID NO: 4 or 5.
In some embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof comprises a linker between the antigen binding domains of the antibody. The
linker may be any kind of linker molecule. Preferably, the linker is a polypeptide. The linkers
may be equal or differ from each other between and within the heavy chain polypeptide and the
light chain polypeptide. Furthermore, the linker may have a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. A preferred peptide linker unit for the heavy
chain domains as for the light chain domains is (G4S) , i.e., GGGGSGGGGS (SEQ ID NO: 6).
Most preferably, SEQ ID NOs: 2 and 4 are linked together by a first peptide linker, and SEQ ID
NOs: 1 and 3 are linked together by a second peptide, wherein the first and second peptide
linkers each comprise the amino acid sequence of SEQ ID NO: 6. The numbers of linker units of
the heavy chain and of the light chain may be equal (symmetrical order) or differ from each other
(asymmetrical order). A peptide linker is preferably long enough to provide an adequate degree
of flexibility to prevent the antigen binding moieties from interfering with each others activity,
for example by steric hindrance, to allow for proper protein folding and, if necessary, to allow
the antibody molecules to interact with two or more, possibly widely spaced, receptors on the
same cell; yet it is preferably short enough to allow the antibody moieties to remain stable in the
cell. Therefore, the length, composition and/or conformation of the peptide linkers can readily
18169100_1 (GHMatters) P41154NZ00
be selected by one skilled in the art in order to optimize the desired properties of the polyvalent
antibody.
In a preferred embodiment of the invention, the anti-IL-4/anti-IL-13 bispecific antibody
or antigen binding fragment thereof is a humanized antibody. Examples of humanized antibody
isotypes include IgA, IgD, IgE, IgG, and IgM. Preferably, the anti-IL-4/anti-IL-13 bispecific
antibody is an IgG antibody. There are four forms of IgG. Preferably, the anti-IL-4/anti-IL-13
bispecific antibody is an IgG4 antibody. In a more preferred embodiment of the invention, the
anti-IL-4/anti-IL-13 bispecific antibody is a humanized IgG4 antibody.
In some embodiments, the anti-IL-4/anti-IL-13 bispecific antibody or antigen binding
fragment thereof further comprises a constant region, e.g., CH1, CH2, CH3, and CL.
Certain embodiments of formulations of the invention also include variants of anti-IL-
4/anti-IL-13 bispecific antibodies or antigen binding fragments thereof. Variants of anti-IL-
4/anti-IL-13 bispecific antibodies may have similar physicochemical properties based on their
high similarity, and therefore are also included within the scope of the invention. Variants are
defined as antibodies with an amino acid sequence that is at least 95%, preferably at least 97%,
for instance at least 98% or 99% homologous to anti-IL-4/anti-IL-13 bispecific antibodies, and
capable of competing for binding to an IL-4 and/or IL-13 polypeptide, an IL-4 and/or IL-13
polypeptide fragment, or an IL-4 and/or IL-13 epitope. Preferably, the variants will ameliorate,
neutralize, or otherwise inhibit IL-4 and/or IL-13 biological activity. Determining competition
for binding to the target can be done by routine methods known to the skilled person in the art.
Preferably the variants are human or humanized antibodies, and preferably are IgG4 molecules.
In preferred embodiments, a variant is at least 95%, 96%, 97%, 98%, or 99% identical in amino
acid sequence with a heavy chain variable region that binds to both IL-13 and IL-4 comprising
the amino acid sequences of SEQ ID NOs: 2, 4, and 5; and a light chain variable region that
binds to both IL-13 and IL-4 comprising the amino acid sequences of SEQ ID NOs: 1 and 3.
The term "variant" refers to an antibody that comprises an amino acid sequence that is altered by
one or more amino acids compared to the amino acid sequences of the anti-IL-4/anti-IL-13
bispecific antibody. The variant may have conservative sequence modifications, including
amino acid substitutions, modifications, additions, and deletions.
Examples of modifications include, but are not limited to, glycosylation, acetylation,
pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups,
18169100_1 (GHMatters) P41154NZ00
proteolytic cleavage, and linkage to a cellular ligand or other protein. Amino acid modifications
can be introduced by standard techniques known in the art, such as site-directed mutagenesis,
molecular cloning, oligonucleotide-directed mutagenesis, and random PCR-mediated
mutagenesis in the nucleic acid encoding the antibodies. Conservative amino acid substitutions
include the ones in which the amino acid residue is replaced with an amino acid residue having
similar structural or chemical properties. Families of amino acid residues having similar side
chains have been defined in the art. These families include amino acids with basic side chains
(e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged
polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan),
nonpolar side chains (e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine,
methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side
chains (e.g., tyrosine, phenylalanine, tryptophan). It will be clear to the skilled artisan that
classifications of amino acid residue families other than the one used above can also be
employed. Furthermore, a variant may have non-conservative amino acid substitutions, e.g.,
replacement of an amino acid with an amino acid residue having different structural or chemical
properties. Similar minor variations may also include amino acid deletions or insertions, or both.
Guidance in determining which amino acid residues may be substituted, modified, inserted, or
deleted without abolishing immunological activity may be found using computer programs well
known in the art. Computer algorithms, such as, inter alia, Gap or Bestfit, which are known to a
person skilled in the art, can be used to optimally align amino acid sequences to be compared and
to define similar or identical amino acid residues. Variants may have the same or different,
either higher or lower, binding affinities compared to an anti-IL-4/anti-IL-13 bispecific antibody,
but are still capable of specifically binding to IL-4 and/or IL-13, and may have the same, higher
or lower, biological activity as the anti-IL-4/anti-IL-13 bispecific antibody.
Embodiments of the invention also include antigen binding fragments of the anti-IL-
4/anti-IL-13 bispecific antibodies. The term "antigen binding domain," "antigen binding region,"
"antigen binding fragment," and similar terms refer to that portion of an antibody which
comprises the amino acid residues that interact with an antigen and confer on the binding agent
its specificity and affinity for the antigen (e.g., the complementary determining regions (CDR)).
The antigen binding region can be derived from any animal species, such as rodents (e.g., rabbit,
rat or hamster) and humans. Preferably, the antigen binding region will be of human origin.
18169100_1 (GHMatters) P41154NZ00
Non-limiting examples of antigen binding fragments include: Fab fragments, F(ab')2 fragments,
Fd fragments, Fv fragments, single chain Fv (scFv) molecules, dAb fragments, and minimal
recognition units consisting of the amino acid residues that mimic the hypervariable region of the
antibody.
In preferred embodiments of the invention, the anti-IL-4/anti-IL-13 bispecific antibody
(or a variant thereof or an antigen binding fragment thereof) will ameliorate, neutralize, or
otherwise inhibit IL-4 and/or IL-13 biological activity in vivo.
In preferred embodiments of the invention, the anti-IL-4/anti-IL-13 bispecific antibodies
(or a variant thereof or an antigen binding fragment thereof) are antagonist antibodies that
ameliorate, neutralize, or otherwise inhibit IL-4 and/or IL-13 biological activity in vivo.
Identification, isolation, preparation, and characterization of anti-IL-4/anti-IL-13
bispecific antibodies or variants or fragments thereof that bind to both IL-13 and IL-4, including
the anti-IL-4/anti-IL-13 bispecific antibody comprising a heavy chain variable region comprising
the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable region comprising
the amino acid sequences of SEQ ID NOs: 1 and 3, have been described in detail in PCT
Publication , which is incorporated herein by reference.
Preferably, the anti-IL-4/anti-IL-13 bispecific antibodies (or a variant thereof or an
antigen binding fragment thereof) are present in the formulations in an amount from about 5
mg/mL to about 200 mg/mL, e.g., about 50 mg/mL to about 150 mg/mL, about 75 mg/mL to
about 125 mg/mL, and about 100 mg/mL. Alternatively, the anti-IL-4/anti-IL-13 bispecific
antibodies (or a variant thereof or an antigen binding fragment thereof) are present in the
formulations in an amount from about 5 mg/mL to about 65 mg/mL, about 66 mg/mL to about
130 mg/mL, about 131 mg/mL to about 200 mg/mL. For example, the anti-IL-4/anti-IL-13
bispecific antibody may be present in the formulation in an amount of about 5 mg/mL, about 10
mg/mL, about 15 mg/mL, about 20 mg/mL, about 25 mg/mL, about 30 mg/mL, about 35
mg/mL, about 40 mg/mL, about 45 mg/mL, about 50 mg/mL, about 55 mg/mL, about 60
mg/mL, about 65 mg/mL, about 70 mg/mL, about 75 mg/mL, about 80 mg/mL, about 85
mg/mL, about 90 mg/mL, about 95 mg/mL, about 100 mg/mL, about 105 mg/mL, about 110
mg/mL, about 115 mg/mL, about 120 mg/mL, about 125 mg/mL, about 130 mg/mL, about 135
mg/mL, about 140 mg/mL, about 145 mg/mL, about 150 mg/mL, about 155 mg/mL, about 160
18169100_1 (GHMatters) P41154NZ00
mg/mL, about 165 mg/mL, about 170 mg/mL, about 175 mg/mL, about 180 mg/mL, about 185
mg/mL, about 190 mg/mL, about 195 mg/mL, or about 200 mg/mL.
In certain exemplary embodiments, the anti-IL-4/anti-IL-13 bispecific antibody is present
in the formulation in an amount of about 100 mg/mL. In another exemplary embodiment, a
humanized IgG4 anti-IL-4/anti-IL-13 bispecific antibody comprising a heavy chain variable
region that binds to both IL-13 and IL-4 comprising the amino acid sequences of SEQ ID NOs: 2
and 4, or 2 and 5; and a light chain variable region that binds to both IL-13 and IL-4 comprising
the amino acid sequences of SEQ ID NOs: 1 and 3 is present in the formulation in an amount of
about 100 mg/mL.
ii. Buffering Agents, Buffering Systems, Ionic Strength, and pH
Buffering agents help to maintain the pH of the formulations in a range that approximates
physiological conditions. Buffers are preferably present in the formulations at a concentration
ranging from about 1 mM to about 50 mM. Suitable buffering agents for use with the instant
invention include both organic and inorganic acids, and salts thereof, such as citrate buffers (e.g.,
monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-
monosodium citrate mixture etc.), succinate buffers (e.g., succinic acid-monosodium succinate
mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture
etc.), tartrate buffers (e.g., tartaric acid-sodium tartrate mixture, tartaric acid-potassium tartrate
mixture, tartaric acid-sodium hydroxide mixture etc.), fumarate buffers (e.g., fumaric acid-
monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-
disodium fumarate mixture etc.), gluconate buffers (e.g., gluconic acid-sodium glyconate
mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture
etc.), oxalate buffers (e.g., oxalic acid-sodium oxalate mixture, oxalic acid-sodium hydroxide
mixture, oxalic acid-potassium oxalate mixture etc.), lactate buffers (e.g., lactic acid-sodium
lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture etc.)
and acetate buffers (e.g., acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide
mixture etc.). Phosphate buffers, carbonate buffers, histidine buffers, trimethylamine salts such
as Tris, HEPES and other such known buffers are also suitable and can be used. Preferably, a
combination of buffers, i.e., two or more buffering agents, is used in the formulations of the
18169100_1 (GHMatters) P41154NZ00
present invention. A combination of two or more buffers is referred to herein as a buffering
system.
The formulations of the invention comprise a buffering system. A buffering system
maintains a physiologically suitable pH. In addition, a buffering system participates in achieving
isotonicity and chemical stability of the formulation. Due to the difficulty of developing a stable
antibody formulation for the bispecific antibody, it is preferable to use a combined buffering
system in order to take advantage of the benefits of two or more buffers. By combining the
benefits of two or more buffers, a more stable antibody formulation is able to be developed.
Preferably, the buffering system is present in the formulations at a concentration from
about 1 mM to about 50 mM, e.g., about 5 mM to about 25 mM, about 5 mM to about 15 mM, or
about 10 mM. Alternatively, the buffering system is present in the formulations at a
concentration from about 1 mM to about 15 mM, about 16 to about 30 mM, about 31 to about 45
mM, or about 46 mM to about 50 mM. For example, the buffering system may be present in the
formulation at a concentration of about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5
mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, about 10 mM, about 11 mM, about 12
mM, about 13 mM, about 14 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM,
about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, about 25
mM, about 26 mM, about 27 mM, about 28 mM, about 29 mM, about 30 mM, about 31 mM,
about 32 mM, about 33 mM, about 34 mM, about 35 mM, about 36 mM, about 37 mM, about 38
mM, about 39 mM, about 40 mM, about 41 mM, about 42 mM, about 43 mM, about 44 mM,
about 45 mM, about 46 mM, about 47 mM, about 48 mM, about 49 mM, and about 50 mM.
More preferably, the buffering system is present in the formulation at a concentration from about
mM to about 15 mM, and even more preferably from about 8 mM to about 12 mM. In a most
preferred embodiment, the buffering system is present at a concentration of about 10 mM.
Preferably, the buffering sytem comprises a Tris buffer and a phosphate buffer.
Preferably, the Tris buffer is present in the formulations at a concentration from about 1 to about
mM. For example, the Tris buffer may be present in the formulation at a concentration of
about 1 mM, about 2 mM, about 3 mM, about 4 mM, or about 5 mM. More preferably, the Tris
buffer is present in the formulations at a concentration from about 2 mM to about 4 mM, and
even more preferably from about 3 mM to about 4 mM. In a most preferred embodiment, the
Tris buffer is present at a concentration of about 3.7 mM.
18169100_1 (GHMatters) P41154NZ00
Preferably, the phosphate buffer is present in the formulations at a concentration from
about 1 to about 10 mM. For example, the phosphate buffer may be present in the formulations
at a concentration of about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6
mM, about 7 mM, about 8 mM, about 9 mM, or about 10 mM. More preferably, the phosphate
buffer is present in the formulations at a concentration from about 3 mM to about 8 mM, and
even more preferably from about 5 mM to about 7 mM. In a most preferred embodiment, the
phosphate buffer is present at a concentration of about 6.3 mM.
In a most preferred embodiment of the invention, the buffering system comprises a Tris
buffer at a concentration of about 3.7 mM and a phosphate buffer at a concentration of about 6.3
mM. This combination of Tris buffer and phosphate buffer in a buffer system is highly unusual
and is not known in the art.
It is also preferable that the buffering system is present in the formulations in a low
concentration, i.e., about 15 mM or less, in order to lower the ionic strength of the formulation.
This is due to the fact that as the ionic strength of the formulation increases, the kinetics of
aggregation of the antibody increases. Decreasing aggregation of the antibody and/or the speed
of aggregation of the antibody is needed in order to improve the stability of the formulation.
In certain embodiments, the formulations of the invention have a pH around pH 7.
Preferably, the pH of the formulations range from about 5.0 to about 8.0. For example, the pH of
the formulations may be about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about
.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about
6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about
7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, and about 8.0. More preferably, the pH
of the formulations may range from about 6.5 to about 7.5. In a most preferred embodiment, the
pH is about 7.0. The formulations exhibit good stability regarding visible particles, sub-visible
particles, low molecular weight proteins, and high molecular weight proteins when the pH of the
formulations is about pH 7. The pH of the formulation may be measured by any means known
to those of skill in the art. A preferred means for measuring pH is using a pH meter with a
micro-electrode. The pH of the formulation may be adjusted using any means known in the art.
Preferred chemicals for altering the pH of the formulations are hydrochloric acid (HCl) and
sodium hydroxide (NaOH).
18169100_1 (GHMatters) P41154NZ00
In certain embodiments, the formulations of the invention have a pH above the isoelectric
point (pI) of the antibody. The isoelectric point is the pH at which a particular molecule or
surface carries no net electrical charge. The pI of the bispecific antibody may be determined by
any means known to those of skill in the art. Preferably, the pI of the bispecific antibody is
determined by denaturated isoelectric focusing. The pI of the anti-IL-4/anti-IL-13 bispecific
antibody comprising a heavy chain variable region comprising the amino acid sequences of SEQ
ID NOs: 2 and 4; and a light chain variable region comprising the amino acid sequences of SEQ
ID NOs: 1 and 3 is 5.8-6.2.
iii. Non-ionic Surfactants
The formulations of the invention may, optionally, further comprise a non-ionic
surfactant. Surfactants are chemical compounds that stabilize biological molecules and/or
general pharmaceutical excipients in a formulation. Surfactants generally protect the molecules
and excipients from air/solution interface induced stresses and solution/surface induced stresses,
which may otherwise result in the aggregation of molecules. Surfactants also prevent visible and
sub-visible particle formation.
Preferably, the non-ionic surfactant is present in the formulations at a concentration from
about 0.01% to about 1% (w/v), e.g., about 0.01% to about 0.5%, about 0.01% to about 0.3%, or
about 0.01% to about 0.2%. Alternatively, the non-ionic surfactant is present in the formulations
at a concentration from about 0.01% to about 0.05% (w/v), about 0.06% to about 0.10% (w/v),
about 0.11% to about 0.15% (w/v), about 0.16% to about 0.20% (w/v), about 0.20% to about
0.30% (w/v), about 0.30% to about 0.40% (w/v), about 0.40% to about 0.50% (w/v), about
0.50% to about 0.60% (w/v), about 0.60% to about 0.70% (w/v), about 0.70% to about 0.80%
(w/v), about 0.80% to about 0.90% (w/v), or about 0.90% to about 1.0% (w/v). For example, the
non-ionic surfactant may be present in the formulations in an amount of about 0.01% (w/v),
about 0.02% (w/v), about 0.03% (w/v), about 0.04% (w/v), about 0.05% (w/v), about 0.06%
(w/v), about 0.07% (w/v), about 0.08% (w/v), about 0.09% (w/v), about 0.1% (w/v), about 0.2%
(w/v), about 0.3% (w/v), about 0.4% (w/v), about 0.5% (w/v), about 0.6% (w/v), about 0.7%
(w/v), about 0.8% (w/v), about 0.9% (w/v), and about 1% (w/v). In particular embodiments, the
non-ionic surfactant is present in the formulations from about 0.05% to about 0.2% (w/v).
18169100_1 (GHMatters) P41154NZ00
Examples of surfactants include, but are not limited to, polysorbates, glycerin,
dicarboxylic acids, oxalic acid, succinic acid, fumaric acids, phthalic acids, and combinations
thereof. Those skilled in the art are aware that other non-ionic surfactants can be used as long as
they are pharmaceutically acceptable, i.e. suitable for administration to subjects. The non-ionic
surfactant is preferably a polysorbate. Examples of polysorbates include polysorbate 20,
polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80. Most preferably, the non-
ionic surfactant is polysorbate 80.
In exemplary embodiments, polysorbate 80 is present in the formulations in an amount
from about 0.01% to about 1% (w/v). For example, polysorbate 80 may be present in the
formulations in an amount of about 0.01% (w/v), about 0.02% (w/v), about 0.03% (w/v), about
0.04% (w/v), about 0.05% (w/v), about 0.06% (w/v), about 0.07% (w/v), about 0.08% (w/v),
about 0.09% (w/v), about 0.1% (w/v), about 0.2% (w/v), about 0.3% (w/v), about 0.4% (w/v),
about 0.5% (w/v), about 0.6% (w/v), about 0.7% (w/v), about 0.8% (w/v), about 0.9% (w/v), and
about 1% (w/v). In particular embodiments, polysorbate 80 is present in the formulations from
about 0.03% to about 0.2% (w/v). For example, polysorbate 80 may be present in an amount
from about 0.01% to about 1% (w/v), about 0.02% to about 0.5% (w/v), and about 0.03% to
about 0.2% (w/v). In most preferred embodiments of the invention, polysorbate 80 is present in
the formulations in an amount of 0.2% (w/v).
iv. Sugars
The formulations of the invention may, optionally, further comprise a sugar. Typically,
sugars are used as a stabilizing agent for high molecular weight proteins or as a cryoprotectant or
as lyoprotectant.
Preferably, the sugar is present in the formulations at a concentration from about 1% to
about 10% (w/v), e.g., about 2% to about 8% (w/v), about 3% to about 7% (w/v), about 4% to
about 6% (w/v), or about 5% (w/v). Alternatively, the sugar is present in the formulations at a
concentration from about 1% to about 3% (w/v), about 3% to about 6% (w/v), or about 6% to
about 10 % (w/v). For example, the sugar may be present in the formulations in an amount of
about 1% (w/v), about 2% (w/v), about 3% (w/v), about 4% (w/v), about 5% (w/v), about 6%
(w/v), about 7% (w/v), about 8% (w/v), about 9% (w/v), or about 10% (w/v). In particular
18169100_1 (GHMatters) P41154NZ00
embodiments, the sugar is present in the formulations from about 3% to about 7% (w/v), and
more preferably about 5%.
Examples of sugars include, but are not limited to, monosaccharides, disaccharides, and
polysaccharides. Examples of saccharides include glucose, sucrose, maltose, trehalose, dextrose,
xylitol, fructose and mannitol. Those skilled in the art are aware that other sugars can be used as
long as they are pharmaceutically acceptable, i.e. suitable for administration to subjects.
Preferably, the sugar is a disaccharide. More preferably, the sugar is sucrose.
In certain embodimens, sucrose is present in the formulations in an amount from about
1% to 10% (w/v). For example, sucrose may be present in the formulation in an amount of about
1% (w/v), about 2% (w/v), about 3% (w/v), about 4% (w/v), about 5% (w/v), about 6% (w/v),
about 7% (w/v), about 8% (w/v), about 9% (w/v), or about 10% (w/v). Preferably, sucrose may
be present in an amount of about 3% to about 7% (w/v), or about 4% to about 6% (w/v). Most
preferably, sucrose is present in the formulations in an amount of about 5% (w/v).
v. Non-ionic Stabilizing Agents
The formulations of the invention may, optionally, further comprise a non-ionic
stabilizing agent. Stabilizing agents refer to a broad category of excipients that can range in
function from a bulking agent to an additive that solubilizes the therapeutic agent or helps to
prevent denaturation or adherence to the container wall. Stabilizing agents also minimize high
molecular weight protein formation.
Preferably, the non-ionic stabilizing agent is present in the formulations at a
concentration from about 1% to about 10% (w/v), e.g., about 2% to about 8% (w/v), about 2% to
about 5% (w/v), about 2% to about 4% (w/v), or about 3% (w/v). Alternatively, the non-ionic
stabilizing agent is present in the formulations at a concentration from about 1% to about 2%
(w/v), about 2% to about 4% (w/v), about 4% to about 6% (w/v), about 6% to about 8% (w/v), or
about 8% to about 10 % (w/v). For example, the non-ionic stabilizing agent may be present in
the formulations in an amount of about 1% (w/v), about 2% (w/v), about 3% (w/v), about 4%
(w/v), about 5% (w/v), about 6% (w/v), about 7% (w/v), about 8% (w/v), about 9% (w/v), or
about 10% (w/v). In particular embodiments, the non-ionic stabilizing agent is present in the
formulations from about 1% to about 5% (w/v), more preferably from about 1% to about 3%
(w/v), and most preferably about 3% (w/v).
18169100_1 (GHMatters) P41154NZ00
Examples of stabilizing agents include, but are not limited to, polyhydric sugar alcohols;
amino acids, such as proline, arginine, lysine, glycine, glutamine, asparagine, histidine, alanine,
ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine etc.; organic sugars or sugar
alcohols, such as lactose, trehalose, stachyose, arabitol, erythritol, mannitol, sorbitol, xylitol,
ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols such as inositol;
polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea,
glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α-monothioglycerol and sodium
thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins, such as human
serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such
as polyvinylpyrrolidone, saccharides, monosaccharides, such as xylose, mannose, fructose,
glucose; disaccharides, such as lactose, maltose and sucrose; trisaccharides such as raffinose;
polysaccharides such as dextran and so on. Those skilled in the art are aware that other non-
ionic stabilizing agents can be used as long as they are pharmaceutically acceptable, i.e. suitable
for administration to subjects. Preferably, the non-ionic stabilizing agent is an amino acid. More
preferably, the non-ionic stabilizing agent is proline or glycine. Most preferably, the non-ionic
stabilizing agent is proline. Alternatively, the non-ionic stabilizing agent is mannitol.
In certain embodimens, proline is present in the formulations in an amount from about
1% to 10% (w/v). For example, proline may be present in the formulation in an amount of about
1% (w/v), about 2% (w/v), about 3% (w/v), about 4% (w/v), about 5% (w/v), about 6% (w/v),
about 7% (w/v), about 8% (w/v), about 9% (w/v), or about 10% (w/v). Preferably, proline may
be present in an amount of about 1% to about 5% (w/v), or about 1% to about 3% (w/v). Most
preferably, proline is present in the formulations in an amount of about 3% (w/v).
In certain alternative embodimens, mannitol is present in the formulations in an amount
from about 1% to 10% (w/v). For example, mannitol may be present in the formulation in an
amount of about 1% (w/v), about 2% (w/v), about 3% (w/v), about 4% (w/v), about 5% (w/v),
about 6% (w/v), about 7% (w/v), about 8% (w/v), about 9% (w/v), or about 10% (w/v).
Preferably, mannitol may be present in an amount of about 1% to about 5% (w/v), or about 1%
to about 3% (w/v). Most preferably, mannitol is present in the formulations in an amount of
about 3% (w/v).
v. Other excipients
18169100_1 (GHMatters) P41154NZ00
Furthermore, the formulations of the invention may, optionally, further comprise other
excipients including, but not limited to, water for injection, diluents, solubilizing agents,
soothing agents, additional buffers, inorganic or organic salts, antioxidants, preservatives,
bulking agents, chelating agents, tonicity agents, or the like. Preferably, however, the
formulations of the invention comprise no other excipients, except those described above. Other
pharmaceutically acceptable carriers, excipients, or stabilizers, such as those described in
Remington's Pharmaceutical Sciences 16 edition, Osol, A. Ed. (1980) may be included in the
formulation provided that they do not adversely affect the desired characteristics of the
formulation. In a particular embodiment, the formulation is substantially free of preservatives,
although, in alternative embodiments, preservatives may be added as necessary. For example,
cryoprotectants or lyoprotectants may be included in lyophilized formulations.
vi. Liquid or lyophilized formulations
The formulations of the invention may either be liquid formulations or lyophilized
formulations. Preferably, the formulations are liquid formulations. More preferably, the liquid
formulations are ready for injection. Alternatively, the formulations may be lyophilized
powders. Preferably, the lyophilized powders are ready to be combined with a solvent just prior
to administration.
vii. Exemplary formulations
In one exemplary embodiment of the invention, the invention provides a liquid antibody
formulation suitable for subcutaneous administration, the formulation comprising:
about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3;
about 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer
concentration of about 3.7 mM and a Phosphate buffer concentration of about 6.3 mM;
about 0.2% (w/v) polysorbate 80;
about 5% (w/v) sucrose; and
about 3% (w/v) proline;
18169100_1 (GHMatters) P41154NZ00
wherein the pH of the formulation is about pH 7.
In another exemplary embodiment of the invention, the invention provides a liquid
antibody formulation suitable for subcutaneous administration, the formulation comprising:
about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3;
about 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer
concentration of about 3.7 mM and a Phosphate buffer concentration of about 6.3 mM;
about 0.2% (w/v) polysorbate 80;
about 5% (w/v) sucrose; and
about 3% (w/v) mannitol;
wherein the pH of the formulation is about pH 7.
In an alternative exemplary embodiment of the invention, the invention provides a stable
lyophilized antibody formulation suitable for subcutaneous administration, the formulation
comprising:
about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3;
about 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer
concentration of about 3.7 mM and a Phosphate buffer concentration of about 6.3 mM;
about 0.2% (w/v) polysorbate 80;
about 5% (w/v) sucrose; and
about 3% (w/v) proline;
wherein the pH of the formulation is about pH 7.
In another alternative exemplary embodiment of the invention, the invention provides a
stable lyophilized antibody formulation suitable for subcutaneous administration, the formulation
comprising:
about 100 mg/mL of a bispecific antibody or an antigen binding fragment thereof,
wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable
18169100_1 (GHMatters) P41154NZ00
region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 1 and 3;
about 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer
concentration of about 3.7 mM and a Phosphate buffer concentration of about 6.3 mM;
about 0.2% (w/v) polysorbate 80;
about 5% (w/v) sucrose; and
about 3% (w/v) mannitol;
wherein the pH of the formulation is about pH 7.
vii. Stability
The formulations of the invention are stable at 2-8°C for at least about 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36 months or more. In exemplary embodiments, they are stable at 2-8°C for at least
about 6 months or more. In other exemplary embodiments, they are stable at 2-8°C for at least
about 9 months. In further exemplary embodiments, they are stable at 2-8°C for at least about 1
year or more, more preferably about 2 years, and even more preferably about 3 years.
C. Modes of Administration
In certain embodiments of the invention, the formulations are suitable for administration
parenterally, intravenously, intramuscularly, intradermally, subcutaneously, or a combination
thereof. The formulations of the invention are suitable for delivery by a variety of techniques.
In preferred embodiments of the invention, the formulation is administered subcutaneously. For
example, it is preferred that formulations containing 100 mg/mL of anti-IL-4/anti-IL-13
bispecific antibody are administered subcutaneously. Therefore, the formulations are preferably
sterile. Methods for making formulations sterile are well known in the art and include, for
example, filtration through sterile filtration membranes or autoclaving the ingredients of the
formulation, with the exception of the antibodies, at about 120°C for about 30 minutes.
D. Dosages and Dosage Forms
Effective doses of the formulations of the invention vary depending upon many different
factors, including means of administration, target site, physiological state of the subject, whether
18169100_1 (GHMatters) P41154NZ00
the subject is human or an animal, other medications administered, and whether treatment is
prophylactic or therapeutic. Usually, the subject is a human, but non-human mammals including
transgenic mammals can also be treated. Treatment dosages may need to be titrated to optimize
safety and efficacy. Preferably, the dose ranges from 100-200 mg/vial.
The formulations of the invention may be administered on multiple occasions. Intervals
between single dosages can be daily, weekly, biweekly, monthly or yearly. Intervals can also be
irregular. In some methods, the dosage is adjusted to achieve a certain plasma binding agent,
such as an antibody, concentration. Dosage and frequency will vary depending on the half-life
of the anti-IL-4/anti-IL-13 bispecific antibody in the subject. In general, human antibodies show
the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman
antibodies.
In further embodiments, the invention provides a pharmaceutical unit dosage form
comprising a therapeutically effective amount of a formulation of the invention for the treatment
of one or more diseases in a subject through administration of the dosage form to the subject. In
a preferred embodiment, the subject is a human. The human may be an adult or may be an
infant. The term "pharmaceutical unit dosage form" refers to a physically discrete unit suitable
as unitary dosages for the subjects to be treated, each unit containing a predetermined quantity of
active compound calculated to produce the desired therapeutic/prophylactic effect in association
with the required citrate buffer and pH.
The unit dosage form may be a container comprising the formulation. Suitable containers
include, but are not limited to, sealed ampoules, vials, bottles, syringes, and test tubes. The
containers may be formed from a variety of materials, such as glass or plastic, and may have a
sterile access port (for example, the container may be a vial having a stopper pierceable by a
hypodermic injection needle). In a preferred embodiment the container is a vial. Generally, the
container should maintain the sterility and stability of the formulation.
In specific embodiments, the formulations are packaged in 7, 10, 15 or 20 mL vials that
are made of clear, colorless type I glass, and closed with a stopper (fluoropolymer-coated
bromobutyl) sealed with flip-of caps with flange (polypropylene).
In specific embodiment, the formulations are secondarily packaged in a container, such as
a cardboard box, that protects the vials from light.
18169100_1 (GHMatters) P41154NZ00
The formulations to be used for in vivo administration must be sterile. That can be
accomplished, for example, by filtration through sterile filtration membranes. For example, the
liquid formulations of the present invention may be sterilized by filtration using a 0.2 μm or a
0.22 μm filter.
E. Methods of Treatment
Further provided herein are methods for treating an IL-4 and/or ILmediated disease
or disorder, the methods comprising administering a formulation of the invention to a subject. In
certain embodiments, the IL-4 and/or ILmediated disease is cancers, inflammation,
autoimmune diseases, infections, cardiovascular diseases, respiratory diseases, neurological
diseases and metabolic diseases.
The formulations of the present invention may be used to treat, suppress or prevent
disease, such as an allergic disease, a Th2-mediated disease, ILmediated disease, IL
mediated disease, and/or IL-4/ILmediated disease. Examples of such diseases include,
Hodgkin's disease, asthma, allergic asthma, atopic dermatitis, atopic allergy, ulcerative colitis,
scleroderma, allergic rhinitis, COPD3 idiopathic pulmonary fibrosis, chronic graft rejection,
bleomycin-induced pulmonary fibrosis, radiation-induced pulmonary fibrosis, pulmonary
granuloma, progressive systemic sclerosis, schistosomiasis, hepatic fibrosis, renal cancer, Burkitt
lymphoma, Hodgkins disease, non~Hodgkins disease, Sezary syndrome, asthma, septic arthritis,
dermatitis herpetiformis, chronic idiopathic urticaria, ulcerative colitis, scleroderma,
hypertrophic scarring, Whipple's Disease, benign prostate hyperplasia, a lung disorder in which
IL-4 receptor plays a role, condition in which IL-4 receptor-mediated epithelial barrier disruption
plays a role, a disorder of the digestive system in which IL-4 receptor plays a role, an allergic
reaction to a medication, Kawasaki disease, sickle cell disease, Churg-Strauss syndrome, Grave's
disease, pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative syndrome,
autoimmune hemolytic anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis, cystic
fibrosis, allergic bronchopulmonary mycosis, chronic obstructive pulmonary disease, bleornycin-
induced pneumopathy and fibrosis, pulmonary alveolar proteinosis, adull respiratory distress
syndrome, sarcoidosis, hyper IgE syndrome, idiopathic hypereosinophil syndrome, an
autoimmune blistering disease, pemphigus vulgaris, bullous pemphigoid, myasthenia gravis,
chronic fatigue syndrome, nephrosis.
18169100_1 (GHMatters) P41154NZ00
The term "allergic disease" refers to a pathological condition in which a patient is
hypersensitized to and mounts an immunologic reaction against a substance that is normally
nonimmunogenic. Allergic disease is generally characterized by activation of mast cells by IgE
resulting in an inflammatory response (e.g.. local response, systemic response) that can result in
symptoms as benign as a runny nose, to life-threatening anaphylactic shock and death. Examples
of allergic disease include, but are not limited to, allergic rhinitis (e.g., hay fever), asthma (e.g.,
allergic asthma), allergic dermatitis (e.g., eczema), contact dermatitis, food allergy and urticaria
(hives).
The term "Th2-mediated disease" refers to a disease in which pathology is produced (in
whole or in part) by an immune response (Th2-type immune response) that is regulated by CD4
Th2 T lymphocytes, which characteristically produce IL-4, IL-5, IL-9 and IL-13. A Th2-type
immune response is associated with the production of certain cytokines (e.g., IL-4, IL-13) and of
certain classes of antibodies (e.g., IgE), and is associate with humoral immunity. Th2-mediated
diseases are characterized by the presence of elevated levels of Th2 cytokines (e.g., IL-4, IL-13)
and/or certain classes of antibodies (e.g., IgE) and include, for example, allergic disease (e.g.,
allergic rhinitis, atopic dermatitis, asthma (e.g., atopic asthma), allergic airways disease (AAD),
anaphylactic shock, conjunctivitis), autoimmune disorders associated with elevated levels of IL-4
and/or IL-13 (e.g., rheumatoid arthritis, host-versus-graft disease, renal disease (e.g., nephritic
syndrome, lupus nephritis)), and infections associated with elevated levels of IL-4 and/or IL-13
(e.g., viral, parasitic, fungal (e.g., C. albicans) infection). Certain cancers are associated with
elevated levels of IL-4 and/or IL-13 or associated with ILinduced and/or ILinduced
cancer cell proliferation (e.g., B cell lymphoma, T cell lymphoma, multiple myeloma, head and
neck cancer, breast cancer and ovarian cancer). These cancers can be treated, suppressed or
prevented using the formulations of the invention.
The term "cancer" refers to or describes the physiological condition in mammals, in
particular humans, which is typically characterized by unregulated cell growth. Examples of
cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
The term "autoimmune disease" refers to a non-malignant disease or disorder arising
from and directed against an individual's own tissues. Examples of autoimmune diseases or
disorders include, but are not limited to, inflammatory responses such as inflammatory skin
diseases including psoriasis and dermatitis; allergic conditions such as eczema and asthma; other
18169100_1 (GHMatters) P41154NZ00
conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis;
diabetes mellitus (e. g. Type I diabetes mellitus or insulin dependent diabetes mellitis); multiple
sclerosis and central nervous system (CNS) inflammatory disorder.
In certain embodiments, the formulations of the invention can be administered in
combination with one or more therapies (e.g., therapies that are not the formulations of the
invention that are currently administered to prevent, treat, manage, and/or ameliorate an IL-4
and/or ILmediated disease. The use of the term "in combination" does not restrict the order
in which therapies are administered to a subject. A first therapy can be administered before (e.g.,
1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24
hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8
weeks, or 12 weeks), concurrently, or after (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1
hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2
weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the administration of a
second therapy to a subject that had, has, or is susceptible to an IL-4 and/or ILmediated
disease. Any additional therapy can be administered in any order with the other additional
therapies. Non-limiting examples of therapies that can be administered in combination with an
antibody of the invention include approved anti-inflammatory agents listed in the U.S.
Pharmacopoeia and/or Physician's Desk Reference.
F. Kits
Certain embodiments of the invention include a kit comprising a formulation of the
invention. The kit may further comprise one or more containers comprising pharmaceutically
acceptable excipients, and include other materials desirable from a commercial and user
standpoint, including filters, needles and syringes. Associated with the kits can be instructions
customarily included in commercial packages of therapeutic, prophylactic or diagnostic products,
that contain information about, for example, the indications, usage, dosage, manufacture,
administration, contra-indications, and/or warnings concerning the use of such therapeutic,
prophylactic or diagnostic products.
18169100_1 (GHMatters) P41154NZ00
EXAMPLES
To help illustrate the invention, the following examples are provided. The examples are
not intended to limit the scope of the invention in any way. In general, the practice of the present
invention employs, unless otherwise indicated, conventional techniques of pharmaceutical
formulation, chemistry, molecular biology, recombinant DNA technology, immunology such as
antibody technology, and standard techniques of polypeptide preparation as described, for
example, in Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory
Press (1989); Antibody Engineering Protocols (Methods in Molecular Biology), volume 51, Ed.:
Paul S., Humana Press (1996); Antibody Engineering: A Practical Approach (Practical Approach
Series, 169), Eds.: McCafferty J. et al., Humana Press (1996); Antibodies: A Laboratory Manual,
Harlow and Lane, Cold Spring Harbor Laboratory Press (1999); and Current Protocols in
Molecular Biology, Eds. Ausubel et al., John Wiley & Sons (1992).
Abbreviations used in Examples 2-6 are:
BD: Biotechnology Development
BsAb: Bispecific Antibody
DLS: Dynamic Light Scattering
DoE: Design of Experiment
DP: Drug Product
DS: Drug Substance
DSC: Differential Scanning Calorimetry
FCM: Flow Cell Microscopy
FDS: Formulated Drug Substance
FT-IR: Fourier Transformed - Infra Red
HAP: HydroxyAPatite chromatography
HDPE: High-Density PolyEthylene
HMW: High Molecular Weight
HPLC: High Performance Liquid Chomatography
IEF: IsoElectroFocusing
IgG: Immunoglobulin G
IL: Interleukin
18169100_1 (GHMatters) P41154NZ00
kDa: kilo Dalton
LMW: Low Molecular Weight
Nd: Not Determined
PEG: PolyEthylene Glycol
PES: PolyEtherSulfone
PS80: PolySorbate 80
PVDF: PolyVinylidene DiFluoride
rpm: round per minute
SC: Subcutaneous
SDS-PAGE: Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis
SEC: Size Exclusion Chromatography
SLS: Static Light Scattering
Sq: Sufficient quantity
TGA: Thermo Gravimetric Analysis
UF/DF: UltraFiltration/DiaFiltration
USP: United States Pharmacopeia
UV-Vis: UltraViolet-Visible
w/v: weight/volume
WFI: Water For Injection
XRPD: X-Ray Powder Diffraction
A humanized IgG4 anti-IL-4/anti-IL-13 bispecific antibody comprising a heavy chain
variable region that binds to both IL-13 and IL-4 comprising the amino acid sequences of SEQ
ID NOs: 2 and 4, and a light chain variable region that binds to both IL-13 and IL-4 comprising
the amino acid sequences of SEQ ID NOs: 1 and 3 (the “Lead Antibody”) was used in the
following examples in order to determine optimal formulation conditions.
The objective of the following formulation studies (Examples 2-6) was to understand the
Lead Antibody’s behavior in solution and in the freeze-dried state (i.e., to identify the major
degradation pathways) and to determine suitable buffer-pH systems and additives that provide a
good stability for the Lead Antibody at about 100 mg/mL for further formulation development.
The following shows the drug substance used in Examples 2-6:
The Lead Antibody post HAP purification step (last step of the downstream processing):
18169100_1 (GHMatters) P41154NZ00
Batch #RSN0169 (study #P5 to P6)
Formulation buffer: sodium phosphate buffer 75 mM, pH 6.7
Concentration: 10.4 mg/mL;
Batches #RSN0169-SZW 320, 326 and 327 (study #P7 to P13)
Formulation buffer: sodium phosphate buffer 59 mM, pH 6.9
Concentration: 4.5 mg/mL;
Batch #RSN0169-SZW 330 (study #P14)
Formulation buffer: sodium phosphate buffer 55 mM, NaCl 20 mM, pH 6.8
Concentration: 4.4 mg/mL; and
Batch # RSN0152 (study #P15 to P21)
Formulation buffer: sodium phosphate buffer 55 mM, NaCl 20 mM, pH 6.8
Concentration: 3.9 mg/mL.
For each formulation assay, the Lead Antibody concentration was adjusted at the end of
the UF/DF in water or final buffer and then diluted further with appropriate amounts of
concentrated buffer and additives solutions up to the desired final formulation (see Table 1 for
details).
Table 1 Details of the formulation adjustment
Initial Initial
Assay
Final concentration
concentration Buffer
P5-7 2 mg/mL Water 1 mg/mL
P12 95 mg/mL Water 85 mg/mL
P13 112 mg/mL Water 100 mg/mL
P14-16 27 mg/mL Water 20 mg/mL
P15 125 mg/mL Water 100 mg/mL
17 46 mg/mL Water 38 mg/mL
P18 46 mg/mL Phosphate/Tris 38 mg/mL
3.5 mM
P20 42 mg/mL Phosphate/Tris 35 mg/mL
3.5 mM
P21 42 mg/mL Phosphate/Tris 35 mg/mL
3.5 mM
a Concentration and buffer after UF/DF and adjustment
b Concentration after dilution with concentrate buffer and additives solutions
18169100_1 (GHMatters) P41154NZ00
Each formulation was sterile filtered (Millex® GV, Millipore, 0.22 µm, PVDF) under
laminar flow and a fraction was dispensed into a type 1 glass vial as appropriate for each stability
time point, except for the freeze/thaw study for which polypropylene tubes were used.
The mechanical stress and thermal stress conditions were determined for the formulations
in Examples 2-6.
In order to evaluate the influence of shaking stress on formulation assays #P5-7, vials
were shaken at 350 rpm for 2 to 15 h at room temperature using a Rota Test 74401 and then
analyzed.
In order to evaluate the influence of syringeability stress on formulation assays #P12, 13,
16-18, and 20, a potential impact of syringeability (i.e., shear stress within the needle) was
assessed with HPLC syringes (Unimetrics Corporation 100 µL) when small volume samples
were available and with Terumo 26G x ½ - 0.45x12 mm syringes when larger volume samples
were available.
In order to evaluate the influence of thermal stress on formulation assays #P5-7 and 13,
vials were stored at 45°C for 1 and 2 weeks, and then analyzed. The relevant temperature for
thermal stress was determined by DSC. Assays #P5-7 and 13 were also stored at 5°C for 2
weeks, and then analyzed.
In order to evaluate the influence of thermal stress on formulation assays #P12, 15, and
21, vials were stored at 5°C for 3 to 6 weeks and analyzed every week. The solutions before
lyophilisation, called Formulated Drug Substance (FDS), for assays #P16-18 and 20 were stored
at 5°C for 4 to 5 weeks and analyzed every week. Reconstituted solutions after lyophilisation for
assays #P14, 16-18, and 20 were stored at 5°C for 24 h and then analyzed.
EXAMPLE 1 – PH OPTIMIZATION
The first step in the formulation development process was to determine the optimal pH
for the Lead Antibody formulation. In order to determine the optimal pH, a low concentration of
Lead Antibody was used (1 mg/ml, as opposed to 100 mg/ml), as this low concentration of Lead
Antibody was sufficient to determine the optimal pH. Table 2 shows the formulations tested in
this study.
18169100_1 (GHMatters) P41154NZ00
Table 2 Assay #P5 pH screening
Formulation #P5x Buffer system pH Concentration
1 Citrate 100 mM 4.5 1 mg/ml
2 Citrate 100 mM 5.0 1 mg/ml
3 Citrate 100 mM 5.5 1 mg/ml
4 Citrate 100 mM 6.0 1 mg/ml
Phosphate 100 mM 6.5 1 mg/ml
6 Phosphate 100 mM 7.0 1 mg/ml
7 Phosphate 100 mM 7.5 1 mg/ml
8 Tris 100 mM 8.0 1 mg/ml
9 Tris 100 mM 8.5 1 mg/ml
In this study, Formulation 1 was not stable because it led to conformational instability for
the Lead Antibody. Specifically, the Lead Antibody tended to unfold. Also, Formulation 9 led
to deamidation. Thus, it was determined that the optimal pH for the Lead Antibody formulation
would be within a narrow range around pH 7.0.
Subsequent studies of other formulation parameters, such as buffers, surfactants, and
stabilizing agents, included higher concentrations of Lead Antibody. These subsequent studies
confirmed the above conclusions regarding the optimal pH for the Lead Antibody formulation
when high concentrations of Lead Antibody were used.
EXAMPLE 2 – BUFFER SYSTEM/IONIC STRENGTH (SALT)
Buffers
The next step in the formulation development process was to determine the optimal
buffer for the Lead Antibody formulation. Several different buffers were tested, such as
histidine, phosphate, Tris, and combinations thereof, in several different assays.
Table 3 Assay #P6 Buffer system screening at 1 mg/ml
Formulation #P6x Buffer system pH Concentration
1 Histidine 10 mM 6.5 1 mg/ml
2 Phosphate 10 mM 6.5 1 mg/ml
3 Phosphate 10 mM 7.0 1 mg/ml
4 Phosphate 10 mM 7.5 1 mg/ml
Tris 10 mM 7.0 1 mg/ml
18169100_1 (GHMatters) P41154NZ00
Formulation #P6x Buffer system pH Concentration
6 Tris 10 mM 7.5 1 mg/ml
7 Phosphate 60 mM 7.0 1 mg/ml
Table 4 Assay #P7 Salt screening at 1 mg/ml
Formulation #P7x Buffer system pH Concentration Additive
1 Phosphate 10 mM 7.0 1 mg/ml NaCl 70 mM
2 Phosphate 10 mM 7.0 1 mg/ml NaCl 140 mM
3 Tris 10 mM 7.0 1 mg/ml NaCl 70 mM
4 Tris 10 mM 7.0 1 mg/ml NaCl 140 mM
Table 5 Assay #P13 Buffer/Salt screening at 100 mg/ml
Formulation #P13x Buffer system pH Concentration Additive
1 Phosphate 10 mM 7.0 100 mg/ml -
2 Phosphate 10 mM 7.0 100 mg/ml NaCl 70 mM
3 Tris 10 mM 7.0 100 mg/ml -
4 Tris 10 mM 7.0 100 mg/ml NaCl 70 mM
Table 6 Buffer systems formulas
Buffer system (acid/base) pH Acid concentration Base concentration
Citric acid / NaOH 4.5 100 mM Sq pH 5.0
Citric acid / NaOH 5.0 100 mM Sq pH 5.0
Citric acid / NaOH 5.5 100 mM Sq pH 5.5
Citric acid / NaOH 6.0 100 mM Sq pH 6.0
Sodium dihydrogen phosphate / NaOH 6.5 100 mM Sq pH 6.5
Sodium dihydrogen phosphate / NaOH 6.5 10 mM Sq pH 6.5
Sodium dihydrogen phosphate / NaOH 7.0 100 mM Sq pH 7.0
Sodium dihydrogen phosphate / NaOH 7.0 60 mM Sq pH 7.0
Sodium dihydrogen phosphate / NaOH 7.0 10 mM Sq pH 7.0
Sodium dihydrogen phosphate / NaOH 7.5 100 mM Sq pH 7.5
Sodium dihydrogen phosphate / NaOH 7.5 10 mM Sq pH 7.5
Phosphoric acid / Tris aminomethan 8.0 Sq pH 8.0 100 mM
Phosphoric acid / Tris aminomethan 8.5 Sq pH 8.5 100 mM
Phosphoric acid / Tris aminomethan 7.0 Sq pH 7.0 10 mM
Phosphoric acid / Tris aminomethan 7.5 Sq pH 7.5 10 mM
18169100_1 (GHMatters) P41154NZ00
Buffer system (acid/base) pH Acid concentration Base concentration
HCl / L-Histidine 6.5 Sq pH 6.5 10 mM
Sodium dihydrogen phosphate / Tris aminomethan 7.0 6.3 mM 3.7 mM
Sodium dihydrogen phosphate / Tris aminomethan 7.0 2.22 mM 1,28 mM
Upon processing and formulation compounding, filtered formulation assays and controls
were free of visible and sub-visible particles, and the SEC analysis showed a purity ≤ 92.0% due
to a starting DS containing 5.5% of HMW.
Onset and denaturation temperatures obtained by DSC indicated a better thermal stability
for the following buffer-pH systems:
• Phosphate pH 6.5 and 7.0: #P5-5, P5-6, P6-2, P6-3
• Tris pH 7.0 and 7.5: #P6-5, P6-6
for which the onset temperature was around 61°C compared for example to 48°C for pH 4.5 and
59°C for the Histidine buffer.
Colloidal stability obtained by SLS indicated a better stability for the following buffer-pH
systems:
• Phosphate pH 7.5: #P6-4
• Tris pH 7.0 and 7.5: #P6-5, P6-6
-4 2
for which the second virial coefficient was close to 3.0 10 mL.mol/g compared for example to
-4 2 -4 2
0.4 10 mL.mol/g for the Histidine buffer and 1.5 10 mL.mol/g for the Phosphate pH 7.0
buffer.
Different levels of particle contamination were observed after 1h30 shaking stress (see
Figure 3).
With regard to visible particles, buffer-pH system candidates showing good stability for
assay #P5 were as follows:
• Phosphate pH 6.5, 7.0 and 7.5: #P5-5, P5-6 and P5-7
• Tris pH 8.0 and 8.5: #P5-8 and P5-9
Assay #6 was performed for these two buffer systems with pHs between 6.5 and 7.5.
Candidates showing the best stability were as follows:
• Phosphate pH 7.0 and 7.5: #P6-3 and P6-4
• Tris pH 7.0 and 7.5: #P6-5 and P6-6
18169100_1 (GHMatters) P41154NZ00
Basic pHs seemed to be better for minimizing particles formation.
Shaking stress and thermal stress (2 weeks at 45°C) are relevant methods for buffer-pH
system discrimination with regard to sub-visible particles.
Buffer-pH system candidates providing a good stability were:
Assay #5: formulations #P5-6 to P5-9, i.e., pH ≥ 7.0
Assay #6 (see Figure 4 and Figure 5):
- Phosphate 7.5: # P6-4
- Tris 7.5: # P6-6
Followed by:
- Phosphate pH 7.0: #P6-3
- Tris pH 7.0: #P6-5
Note that the Histidine buffer (#P6-1) showed, for all stressed conditions, an important
destabilizing effect.
HIAC measurements confirmed the visual inspection: basic pHs were better for
minimizing particle formation. Furthermore, at the same pH, Phosphate-based formulations
provided slightly less sub-visible particles than Tris buffering-system.
Regarding assay #5 and 6, thermal stress showed interesting results for both HMW and
LMW. Note that formulation #P5-1 (pH 4.5) was totally degraded after 1 week at 45°C; so was
formulation #P5-2 after 2 weeks at 45°C. These two samples will be cast out of the following
analysis.
With regards to HMW, results after 2 weeks at 45°C were similar for formulations #P5-6
to P5-9 (pH ≥ 7.0) and better for #P5-5 to P5-3 as pH decreased from 6.5 to 5.5. For assay #6,
this tendency was confirmed and buffer-pH system candidates providing a good stability were
(see Figure 6):
• Phosphate pH 6.5: #P6-2
• Tris pH 7.0: #P6-5
• Histidine pH 6.5: #P6-5
Thus, pH 6.5 provided a better stability for minimizing HMW formation than pH 7.0,
which itself was better than pH 7.5. Furthermore, at the same pH (7.0 and 7.5), Tris-based
formulations provided slightly less HMW than Phosphate buffering-system.
18169100_1 (GHMatters) P41154NZ00
With regards to LMW, formulations #P5-3 to P5-5 (pH ≤ 6.5) showed a good stability
after 2 weeks at 45°C. Formations of substantial LMW and extra bands on SDS-PAGE gel
occurred for formulation #P5-6 to P5-9 (7.0 ≤ pH ≤ 8.5). LMW degradation was more
pronounced for formulation #P5-9 (Tris pH 8.5) (see Figure 7) and extra bands on SDS-PAGE
gel were particularly visible for #P5-7 (Phosphate pH 7.5) (see Figure 8). Note that the products
of degradation seemed different for Phosphate and Tris buffered systems.
Assay #6 confirmed these conclusions and showed that for the same pH, Phosphate-based
formulations provided slightly more LMW than Tris buffering-systems.
Regarding HMW and LMW, acidic pHs seemed to present a better stability than basic
ones, with a slight advantage for Tris over Phosphate buffering-system.
Thermal stress at 45°C for 4 weeks was a relevant mean to force chemical degradation of
the Lead Antibody (i.e., change in acidic pattern) evidenced by IEF, and therefore to select
buffer-pH systems providing a good stability for the Lead Antibody (see Figure 9). The least
stable formulations were Tris pH 8.5 (#P5-9) and Phosphate pH 7.5 (#P6-4), as the isoform
pattern, both presented 2 extra acid forms and the major form became minor. The buffer-pH
system candidate showing a good stability was Tris pH 7.0 (#P6-5).
In conclusion, based on initial state analysis and stress program results on assays #P5 and
6 (1 mg/mL solutions), the pH has been set at 7.0. This selection is a compromise between a
good stability regarding visible and sub-visible particles (basic pHs) and stability regarding
HMW and LMW (acid pHs). Regarding buffering systems, both Phosphate and Tris showed
advantages for the selected pH: Phosphate regarding visible/sub-visible particles, and Tris
regarding HMW and LMW.
Note that for the first additives assessment, buffering systems Phosphate 10 mM or Tris 10
mM have been used:
• To confirm the above results on 100 mg/mL Lead Antibody solutions,
• And to test the freeze-drying process on both buffering systems separately.
The results above were confirmed and both buffering systems (#P14-3 and P14-8)
showed good results during the freeze drying process (see Figure 19).
At pH 7.0, Phosphate has a stronger buffering capacity than Tris; however, unlike Tris, its
base has a tendency to precipitate during freezing steps. To combine the advantages of both Tris
and Phosphate, a mix of these two buffering systems has been selected: Phosphate 6.3 mM and
18169100_1 (GHMatters) P41154NZ00
Tris 3.7 mM. Even though the use of Tris buffer or phosphate buffer is known in the art (the use
of each one separately), the combination of Tris buffer and phosphate buffer in a buffer system is
highly unusual and is not known in the art.
Conductivity (pH and buffer selection)
The solution before lyophilisation had a conductivity of around 300 µS/cm, which gives a
theoretical conductivity of 850 µS/cm for the DP after reconstitution.
We first tried a commonly used buffer for a mAb: Histidine, in its buffering region at pH
6.2 and 6.6 and at a concentration of 10 mM. At pH 6.2, an insolubility issue had been
encountered with precipitation of the Lead Antibody at room temperature (see Fig 29). At pH
6.6, the solution was slightly opalescent at room temperature, the second virial coefficient was
-4 2
low 0.4 10 mL.mol/g . Unlike most mAbs, Histidine is not a good buffer for the Lead
Antibody.
Then we tried another commonly used buffer: Phosphate in its buffering region at pH 6.5,
7.0 and 7.5, and at a concentration of 10 mM. For pH 6.5 and 7.0, the second virial coefficient
-4 2
was below 1.5 10 mL.mol/g , which means a low colloidal stability. For pH 7.5, the second
-4 2
virial coefficient was close to 3.0 10 mL.mol/g , which means a good colloidal stability,
however a thermal stress (2 weeks at 45°C) showed a decrease of purity (both HMW and LMW
increase) more important than for pH 6.5 and 7.0. Phosphate is a good buffer, however at acidic
pH the colloidal stability is low, and at basic pH the Lead Antibody is sensitive to thermal stress.
In order to expand the buffer screening, Tris was tested in its buffering region at pH 7.0,
and 7.5, and at a concentration of 10 mM. Both pHs presented a good colloidal stability with a
-4 2
viral coefficient close to 3.0 10 mL.mol/g . Thermal stress (2 weeks at 45°C) showed a
decrease of purity (both HMW and LMW increase) more important for pH 7.5 than for pH 7.0.
However, Tris at pH 7.0 provided a much better stability regarding HMW and a slightly better
stability regarding LMW than Phosphate at the same pH. Tris pH 7.0 is a better buffering
system than Tris pH 7.5 and phosphate pH 7.0. Although, in order to obtain a good buffering
capacity of Tris at this pH (pka = 8.1), the amount required would be greater to the maximum
used in a commercialized product.
18169100_1 (GHMatters) P41154NZ00
In order to optimize the buffer for the Lead Antibody, a combination of Phosphate
6.5mM/Tris 3.7mM was selected to obtain a good buffering capacity at pH 7.0 due to Phosphate
(pka = 7.2), and a good stabilization of the Lead Antibody due to Tris.
As stated above, even though the use of Tris buffer or phosphate buffer is known in the
art (the use of each one separately), the combination of Tris buffer and phosphate buffer in a
buffer system is highly unusual and is not known in the art.
Ionic strength/Salt concentration
Sodium Chloride (NaCl) was tested with the two selected buffer-pH candidates at a
concentration of 70 mM on 100 mg/mL Lead Antibody solutions.
Onset and denaturation temperatures obtained by DSC as well as colloidal stability
obtained by SLS did not indicate any substantial effect of NaCl on the stability of the solutions.
After mechanical stress of formulation assay #P13 and two weeks storage at 5°C of the same
formulation, candidates #P13-1 and P13-3, i.e. without NaCl, showed a better stability regarding
HMW formation (see Figure 10). Same c/c in Figure 33.
Increasing the salt concentration caused an increase in the ionic strength, which caused an
increase in the kinetics of aggregation of the Lead Antibody. Thus, it was determined that the
formulation should not contain salt or an osmotic agent. In addition, it was determined that the
optimal formulation should comprise a low concentration of buffer in order to have a low ionic
strength.
EXAMPLE 3 – SURFACTANT
The next step in the formulation development process was to determine the optimal
excipients for the Lead Antibody formulation. The excipients must be sufficient to stabilize the
Lead Antibody, and be compatible with lyophilisation. Several different surfactants were tested,
such as polysorbates and poloxamers, in various concentrations.
Table 7 Assay #P12 Additives screening at 85 mg/ml
Formulation #P12 Buffer pH Concentration Additive 1 Additive 2
x system
1 Phosphate 10 7.0 85 mg/ml PS80 0.01% (w/v) Glycine 1% (w/v) (130
mM mM)
3 Phosphate 10 7.0 85 mg/ml PS80 0.01% (w/v) Sucrose 5% (w/v)
18169100_1 (GHMatters) P41154NZ00
Formulation #P12 Buffer pH Concentration Additive 1 Additive 2
x system
4 Phosphate 10 7.0 85 mg/ml PS80 0.01% (w/v) Trehalose 5% (w/v)
Phosphate 10
7.0 85 mg/ml PS80 0.01% (w/v) -
6 Phosphate 10 7.0 85 mg/ml PS80 0.1% (w/v) -
7 Phosphate 10 7.0 85 mg/ml PS20 0.01% (w/v) -
8 Phosphate 10 7.0 85 mg/ml PS20 0.1% (w/v) -
9 Phosphate 10 7.0 85 mg/ml Poloxamer 0.05% -
mM (w/v)
Phosphate 10 7.0 85 mg/ml Poloxamer 0.1% (w/v) -
11 Phosphate 10 7.0 85 mg/ml - -
Table 8 Assay #P23 Additives screening at 100 mg/ml
Formulation #P23x Buffer system pH Concentration Additive
1 Tris / Phosphate 10 mM 7.0 100 mg/ml PS80 0.1% (w/v)
2 Tris / Phosphate 10 mM 7.0 100 mg/ml PS80 0.2% (w/v)
3 Tris / Phosphate 10 mM 7.0 100 mg/ml PS80 0.3% (w/v)
Immediately after 0.22 µm filtration, formulation assays and controls were free of visible
and sub-visible particles. SEC analysis showed a purity ≤ 92.0% due to concentration of the
Lead Antibody from 4.5 mg/mL to 100 mg/mL (starting DS contained 3.0% HMW).
Mechanical stress was a relevant mean to discriminate between formulation candidates.
Due to availability of a limited amount of starting material, standard visual observation was not
possible and therefore observation in capillary under a magnifying glass was used. With regard
to visible/sub-visible particles, candidates showing a good stability for assay #12 were as follows
(see Figure 11):
• PS80 0.1 %: #P12-6
• PS20 0.1 %: #P12-8
18169100_1 (GHMatters) P41154NZ00
Among the surfactants tested, none had an impact on HMW formation compared to the
formulation without surfactant except for #P12-8 (PS20 0.1 %), which had a slight negative
effect over six weeks storage at 5°C (see Figure 12).
To conclude, there was no strong difference between surfactants. The following
surfactant: PS80, was selected to prevent visible/sub-visible particle formation.
Next, various concentrations of PS80 were tested in the Lead Antibody formulation (see
Table 23). PS80 concentrations from 0.05-0.2% were tested for shaking stress for 15 hours at
350 rpm (room temperature). The samples were analysed by flow cell microscopy, and the
results are shown in Table 9. Table 9 shows that a PS80 concentration between 0.05 to 0.2%
had an equivalent stabilizing effect for all concentrations regarding shaking stress. Thus, a PS80
concentration of 0.05 to 0.2% can be used in the formulation.
Table 9 – PS80 concentration
15h at 350 rpm at room temperature
≥ 2 µm ≥ 10 µm ≥ 25 µm
2589 148 21
F2 (0.05%PS80)
975 32 2
F3 (0.07%PS80)
698 58 3
F4 (0.1%PS80)
1969 98 16
F5 (0.2%PS80)
FCM: particle number per mL
EXAMPLE 4 – SUCROSE
As stated above, the next step in the formulation development process was to determine
the optimal excipients for the Lead Antibody formulation. The excipients must be sufficient to
stabilize the Lead Antibody, and be compatible with lyophilisation. Several different sugars
were tested, such as sucrose, trehalose, and mannitol, in various concentrations.
Table 10 Assay #P14 Additives screening for a lyophilisate
Form. #P14x Buffer system pH Strength Additive 1 Additive 2 Additive 3
1 Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) - -
2 Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) Sucrose 10% (w/v) -
3 Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) Sucrose 5% (w/v) Mannitol 3% (w/v)
4 Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) NaCl 70 mM Mannitol 3% (w/v)
Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) NaCl 70 mM Mannitol 3% (w/v)
6 Phosphate 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) Glycine 1% (w/v) Mannitol 3% (w/v)
18169100_1 (GHMatters) P41154NZ00
Form. #P14x Buffer system pH Strength Additive 1 Additive 2 Additive 3
7 Phosphate 10 mM 7.0 100 mg/vial PS80 0.3% (w/v) Sucrose 5% (w/v) Mannitol 3% (w/v)
8 Tris 10 mM 7.0 100 mg/vial PS80 0.1% (w/v) Sucrose 5% (w/v) Mannitol 3% (w/v)
Table 11 Assay #P15 Additives screening at 100 mg/ml DoE
Form. Buffer pH Conc. Additive 1 Additive 2 Additive 3 Additive 4
#P15x system
1 Phosphate 7.0 100 PS80 0.01% Sucrose 10% - Proline 5.8%
mM mg/ml (w/v) (w/v) (w/v)
2 Phosphate 7.0 100 PS80 0.01% Mannitol 3% - Proline 5.8%
mM mg/ml (w/v) (w/v) (w/v)
3 Phosphate 7.0 100 PS80 0.01% Trehalose - -
mM mg/ml (w/v) 10% (w/v)
4 Phosphate 7.0 100 PS80 0.01% - Ethanol 2% Glutamic acid
mM mg/ml (w/v) (w/v) 7.3% (w/v)
Phosphate 7.0 100 PS80 0.01% - PEG 400 1% Aspartate 8.7%
mM mg/ml (w/v) (w/v) (w/v)
6 Phosphate 7.0 100 PS80 0.01% Trehalose - Aspartate 8.7%
mM mg/ml (w/v) 10% (w/v) (w/v)
7 Phosphate 7.0 100 PS80 0.01% Sucrose 10% Glycerol 5% Glycine 1.9 %
mM mg/ml (w/v) (w/v) (w/v) (w/v)
8 Phosphate 7.0 100 PS80 0.01% Mannitol 3% PEG 400 1% -
mM mg/ml (w/v) (w/v) (w/v)
9 Tris 10 mM 7.0 100 PS80 0.01% Trehalose PEG 400 1% Proline 5.8%
mg/ml (w/v) 10% (w/v) (w/v) (w/v)
Tris 10 mM 7.0 100 PS80 0.01% Mannitol 3% - Aspartate 8.7%
mg/ml (w/v) (w/v) (w/v)
11 Tris 10 mM 100 PS80 0.01% Sucrose 10% Ethanol 2% -
mg/ml (w/v) (w/v) (w/v)
12 Tris 10 mM 7.0 100 PS80 0.01% - Glycerol 5% -
mg/ml (w/v) (w/v)
13 Tris 10 mM 100 PS80 0.01% Trehalose Glycerol 5% Glutamic acid
mg/ml (w/v) 10% (w/v) (w/v) 7.3% (w/v)
14 Tris 10 mM 100 PS80 0.01% - - Glycine 1.9 %
mg/ml (w/v) (w/v)
Tris 10 mM 7.0 100 PS80 0.01% Sucrose 10% - Glutamic acid
mg/ml (w/v) (w/v) 7.3% (w/v)
16 Tris 10 mM 7.0 100 PS80 0.01% Mannitol 3% Ethanol 2% Glycine 1.9 %
mg/ml (w/v) (w/v) (w/v) (w/v)
18169100_1 (GHMatters) P41154NZ00
Table 12 Assay #P16 Additives screening and process development for a lyophilisate
Form. Buffer pH Strength Additive 1 Additive 2 Additive 3 Additive 4
#P16x system
1 Phosphate 10 7.0 100 PS80 0.1% Sucrose 5% Mannitol 3% -
mM mg/vial (w/v) (w/v) (w/v)
2 Phosphate 10 7.0 100 PS80 0.1% Trehalose 5% Mannitol 3% -
mM mg/vial (w/v) (w/v) (w/v)
3 Phosphate 10 7.0 100 PS80 0.05% Sucrose 5% Mannitol 3% -
mM mg/vial (w/v) (w/v) (w/v)
4 Phosphate 10 7.0 100 PS80 0.1% Sucrose 5% Mannitol 3% PEG 4000 1%
mM mg/vial (w/v) (w/v) (w/v) (w/v)
Table 13 Assay #P17FDS Additives screening at 38 mg/mL
Form. #P17x Buffer system pH Concentration Additive 1 Additive 2 Additive 3
1 Tris / Phosphate 3.3 mM 7.0 38 mg/mL PS80 0.033% Sucrose 3.33% -
(w/v) (w/v)
2 Tris / Phosphate 3.3 mM 7.0 38 mg/mL PS80 0.033% Sucrose 1.67% Mannitol 1%
(w/v) (w/v) (w/v)
3 Tris / Phosphate 3.3 mM 7.0 38 mg/mL PS80 0.033% - Glycine 0.37%
(w/v) (w/v)
Table 14 Assay #P17 Additives screening and process development for a lyophilisate
Form. #P17x Buffer system pH Strength Additive 1 Additive 2 Additive 3
1 Tris / Phosphate 10 mM 7.0 190 PS80 0.1% Sucrose 10% -
mg/vial (w/v) (w/v)
2 Tris / Phosphate 10 mM 7.0 190 PS80 0.1% Sucrose 5% (w/v) Mannitol 3% (w/v)
mg/vial (w/v)
3 Tris / Phosphate 10 mM 7.0 190 PS80 0.1% - Glycine 2.2%
mg/vial (w/v) (w/v)
18169100_1 (GHMatters) P41154NZ00
In conclusion, based upon the above studies, sucrose was chosen as an excipient because
it stabilized the Lead Antibody. In addition, it is well known that sucrose is a lyoprotectant so it
will improve the lyophilized formulation. In fact, lyophilization without sucrose leads to an
increase in HMW (see Fig 19). Further, 5% sucrose was found to be optimal for the formulation.
EXAMPLE 5 – STABILIZING AGENTS
As stated above, the next step in the formulation development process was to determine
the optimal excipients for the Lead Antibody formulation. The excipients must be sufficient to
stabilize the Lead Antibody, and be compatible with lyophilisation. Several different stabilizing
agents were tested, such as mannitol, aspartate, proline, glycine, arginine and leucine, in various
concentrations. This can be seen in the Tables below and in Tables 10-14 above.
Table 15 Assay #P18 Additives screening and process development for a lyophilisate
Form. #P18x Buffer system pH Strength Additive 1 Additive 2 Additive 3
1 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Mannitol 3% (w/v)
mg/vial (w/v) (w/v)
2 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Aspartate 4.3%
mg/vial (w/v) (w/v) (w/v)
3 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Proline 5.8% (w/v)
mg/vial (w/v) (w/v)
Table 16 Assay #P20FDS Additives screening at 35 mg/mL
Form. #P20x Buffer system pH Concentration Additive 1 Additive 2 Additive 3
1 Tris / Phosphate 3.5 mM 7.0 35 mg/mL PS80 0.07% Sucrose1.75% Mannitol
(w/v) (w/v) 1.05% (w/v)
2 Tris / Phosphate 3.5 mM 7.0 35 mg/mL PS80 0.07% Sucrose1.75% Aspartate
(w/v) (w/v) 1.05% (w/v)
3 Tris / Phosphate 3.5 mM 7.0 35 mg/mL PS80 0.07% Sucrose1.75% Proline 1.05%
(w/v) (w/v) (w/v)
4 Tris / Phosphate 3.5 mM 7.0 35 mg/mL PS80 0.07% Sucrose1.75% Glycine 1.05%
(w/v) (w/v) (w/v)
Tris / Phosphate 3.5 mM 7.0 35 mg/mL PS80 0.07% Sucrose1.75% Arginine
(w/v) (w/v) 1.05% (w/v)
18169100_1 (GHMatters) P41154NZ00
Table 17 Assay #P20 Additives screening and process development for a lyophilisate
Form. #P20x Buffer system pH Strength Additive 1 Additive 2 Additive 3
1 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Mannitol 3% (w/v)
mg/vial (w/v) (w/v)
2 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Aspartate 3%
mg/vial (w/v) (w/v) (w/v)
3 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Proline 3% (w/v)
mg/vial (w/v) (w/v)
4 Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Glycine 3% (w/v)
mg/vial (w/v) (w/v)
Tris / Phosphate 10 mM 7.0 175 PS80 0.1% Sucrose 5% Arginine 3% (w/v)
mg/vial (w/v) (w/v)
Table 18 Assay #P21 Additives screening at 35 mg/ml
Form. Buffer pH Concentration Additives 1 Additive 2 Additive 3
#P21x system
1 Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% Mannitol 3% (w/v)
Phosphate 3.5 (w/v) (w/v)
2 Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% Sulfobutyl-ether-β-
Phosphate 3.5
(w/v) (w/v) cyclodextrine 3% (w/v)
3 Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% N-acetyl-cystéine 3% (w/v)
Phosphate 3.5 (w/v) (w/v)
4 Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% Leucine 0.3% (w/v)
Phosphate 3.5 (w/v) (w/v)
Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% L-Lysine monochlorhydrate
Phosphate 3.5 (w/v) (w/v) 3% (w/v)
6 Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% N-acetyl-cystéine 0.03% (w/v)
Phosphate 3.5 (w/v) (w/v)
Tris / 7.0 35 mg/ml PS80 0.01% Sucrose 1% Mannitol 3% (w/v)
Phosphate 3.5 (w/v) (w/v)
8 Tris / 7.0 35 mg/ml PS80 0.01% - -
Phosphate 3.5 (w/v)
c Same formulation as #P21-1 but this sample is inerted thanks to nitrogen while stored at 5°C
18169100_1 (GHMatters) P41154NZ00
The aim of these screenings was to find an additive to stabilize further the Lead Antibody
with regard to HMW formation (assay #12, 15, 20-FDS, and 21). Due to the high sensitivity of
the Lead Antibody to aggregation, the intended long term storage temperature (i.e., 5°C) was
found to be relevant to monitor the effect of the additives.
A Design of Experiment (DoE)-Screening model, first degree, D-optimal matrix- was
done to screen the effect of different sugars, polyols, amino acids and solvents on HMW
formation (assay #15). The outcome of this DoE is summarized in Table 19.
Table 19 Outcome of assay #15 (DoE) regarding additives screening
Parameters HMW DSC Conclusion
Sugars and Slight stabilisation by Mannitol Slight stabilisation by Sucrose and Slight positive effect of sugars
Polyols Trehalose and polyols
Amino acids Strong stabilisation by Aspartate and Stabilisation by Aspartate and Positive effect of Aspartate,
slight stabilisation by Glycine, Proline slightly by Glycine and Proline Glycine and Proline
and Glutamine
Solvents Strong destabilisation by ethanol Strong destabilisation by ethanol No or destabilizing effect of
solvents
Buffer systems No effect ND No difference between buffer
systems
The additives found to have an effect on HMW were tested separately in assay #12 and
-FDS:
• Amino acids glycine (#P12-1 and P20FDS) and proline (#P20FDS) were found to
have the best effect in minimizing HMW formation (see Figure 13 and Figure 14),
• Mannitol (#P20FDS) came afterwards (see Figure 14),
• Followed by sucrose (#P12-3) and trehalose (#P12-4), which were much less efficient
(see Figure 13),
• Finally, a positive effect of aspartate 8% (#P20FDS) was not confirmed at a
concentration of 4% (see Figure 14).
Several other additives were tested during assay #21:
• Lysine (#P21-5) was found to have a slight positive effect on HMW formation (see
Figure 15),
18169100_1 (GHMatters) P41154NZ00
• Mannitol (#P21-1) was found to be the best in this assay.
It was found that the addition of proline to the formulation had two effects: it controlled
HMW formation by reducing the rate of aggregation in the liquid formulation, and it acted as a
bulking agent to make the cake more elegant in the lyophilized formulation. It was also found
that the addition of mannitol to the lyophilized formulation caused the cake to be elegant.
Next, various concentrations of proline were tested in the lead antibody formulation (see
Table 23). Concentrations of 1% and 3% were tested. The samples were analysed by UPLC,
and the results are shown in Tables 20 and 21, and in Figure 16. Tables 20 and 21 show that
either a proline concentration of 1 or 3% can be used in the formulation. These data also confirm
the positive effect of proline on HMW kinetics. Furthermore, the cake is slightly more elegant
(less retracted) with proline 3%, which confirms the role of proline as a ballast (results not
shown).
Table 20 – 1% proline
F1 (1%proline)
stability n° 2
Time (h) % Monomer (M) 1/M 1/M - 1/M0 %HMW
0 95.0 0.01053 4.2
3.5 92.6 0.01080 0.00027 6.6
7 90.6 0.01104 0.00051 8.7
24 82.0 0.01220 0.00167 17.4
Table 21 – 3% proline
F5 (3%proline)
stability n° 2
Time (h) % Monomer (M) 1/M 1/M - 1/M0 %HMW
0 95.3 0.01049 3.8
3.5 93.2 0.01073 0.00024 6
7 91.6 0.01092 0.00042 7.8
24 84.1 0.01189 0.00140 15.1
In conclusion, although HMW formation has been significantly reduced by the addition of
excipients, namely mannitol and amino acids such as glycine and proline, the beneficial effect at
a Lead Antibody concentration of 100 mg/mL is not strong enough to achieve satisfactory shelf
life. Hence a lyophilised formulation, along with a lyophilisation process has been developed.
18169100_1 (GHMatters) P41154NZ00
EXAMPLE 6 – LYOPHILIZED FORMULATIONS
For the freeze/drying process, 5 to 5.5 mL of the desired FDS prototype ranging from
Lead Antibody concentration 20-38 mg/mL was dispensed into 15 mL vials (see as examples
Table 13 and Table 14).
The freeze/drying process was done on pre-concentrated solution at 20 to 38 mg/mL in
the close to final formulation of 5 to 5.5 mL dispensed into 15 mL vials.
Three different types of lyophilized systems from Usifroid have been used: PL45 (assay
#14), SMH-300 (assay #17), and SMH-90 (assay #16, 18, 20). For details of the lyophilisation
cycles see Table 22. The slope of temperature changing between lyophilisation steps is
1°C/min.
Table 22 Lyophilisation cycles used for each assay
Assay Freezing Length Primary Duration of Secondary Duration of Holding
# Temp. at T drying primary drying Secondary time at
Freeze
T Temp. drying Temp. drying step
Freeze
°C
step
14 -45°C 100 min -10°C 20 h 30°C 7 h 14 h
16 -42°C 60 min -25°C 46 h 30°C 18 h 18 h
17 -45°C 60 min -25°C 51 h 30°C 21 h 20h
18 -42°C 60 min -25°C 37 h 30°C 18 h 18 h
-42°C 60 min -25°C 53 h 40°C 18 h 3 h
a Set during the experiment according to the product temperature measurement
b The cycle is ended only during standard working time hours
The dried substance obtained was then reconstituted at the target concentration of 100
mg/mL by adding the appropriate amount of WFI (1.0 to 1.6 mL).
For lyophilisation assays #P16-20, 1 mL FDS solutions were frozen at -20°C, thawed at
room temperature once and then analyzed.
Freezing and thawing of intermediate DS (end of HAP step – BD) was also tested (assay
#9). For this assay, 20 mL of DS in 50 mL HDPE Nalgene bottles were frozen at both -20°C and
-70°C, thawed at room temperature one time and then analyzed.
The following analytical methods were performed:
• Visual inspection for appearance (clarity and color)
• Light obscuration (HIAC) for quantification of sub-visible particles
• SEC for protein purity
18169100_1 (GHMatters) P41154NZ00
• SDS-PAGE for protein purity
• IEF for charge heterogeneity
• FCM for quantification of sub-visible particles
• DLS for aggregation
• DSC for temperature of denaturation
• SLS for colloidal stability
• FT-IR spectroscopy for secondary structure
• Fluorescence spectroscopy for tertiary structure
• Karl ficher for residual water percentage determination (for lyophilisate)
• XRPD for crystalline/amorphous matrix determination of the cake (for lyophilisate)
The main criteria for the selection of the formulations and lyophilisation process were:
The following parameters were monitored:
• Stability of Lead Antibody during the lyophilisation process
• Stability of the reconstituted solution
• Stability of the FDS (solution before lyophilisation)
• Elegance of the cake
• Reconstitution time
• Stability of the cake
The freeze drying cycle has been selected to avoid collapse of the cakes (see Table 22):
• The freezing temperature has been set below the temperature of complete solidification
i.e., slightly below the glass transition temperature (Tg’), which has been measured by
DSC for each FDS candidate (solution before lyophilisation) (see Figure 17).
• The primary drying temperature has been set such that the temperature of the sample
stays below the collapse temperature, which is close to Tg’ (see Figure 17).
The cakes obtained during the various lyophilisation assays were all elegant (see Figure
18) and the reconstitution time was within five minutes. Even if those parameters are important
to monitor during the development, they were not relevant to discriminate between formulations.
During the freezing step, a cooling rate of 1°C/min was selected to avoid significant shifts
in Lead Antibody concentration and pH. Secondary drying temperature was selected (see Table
22) to obtain a level of the residual water in the cake measured by Karl fisher below 1%.
18169100_1 (GHMatters) P41154NZ00
Stabilization of Lead Antibody was assessed by SEC and SDS-PAGE for purity, and DLS
and FCM for particle formation. The relevant criteria to discriminate between formulations were
the level of HMW before and after reconstitution and sub-visible particles counting after
reconstitution.
To evaluate the impact of the lyophilisation process, the level of HMW before
lyophilisation and after reconstitution was represented for each formulation, as well as the
increase of this level - in percentage relative to the level before lyophilisation (see Figure 19 and
Figure 20). A dotted line indicates on each figure an increase of 10%. Candidates providing a
good stability were:
• Phosphate with Sucrose 10 %: #P14-2
• Phosphate and Tris with Sucrose 5 % + Mannitol 3 %: #P14-3 and P14-8
• Phosphate with Mannitol 3 % + Glycine 1 %: #P14-6
• Tris/Phosphate with Sucrose 5 % + Mannitol 3 %: #P20-1
• Tris/Phosphate with Sucrose 5 % + Aspartate 3 %: #P20-2
• Tris/Phosphate with Sucrose 5 % + Proline 3 %: #P20-3
• Tris/Phosphate with Sucrose 5 % + Glycine 3 %: #P20-4
Note that without any excipients (#P14-1), the Lead Antibody is strongly unstable to the
lyophilisation process, as an increase of around 130% was observed for HMW before and after
lyophilisation. This result was expected as a freeze/thaw cycle done on the DS at -20°C and -
70°C (assay #9) showed a strong destabilization of Lead Antibody (see Figure 21) – freezing
being the first step of lyophilisation process.
Regarding sub-visible particles, a comparison between the reconstituted solutions by
FCM showed a better stability for the following candidates:
• Tris/Phosphate with Sucrose 5 % + Proline 3 %: #P20-3
• Tris/Phosphate with Sucrose 5 % + Glycine 3 %: #P20-4
Note: not determined for assay #14
To stabilize the Lead Antibody after reconstitution of the cake, excipients previously
found to slow down aggregation were used (see Section regarding Excipients Screening for a
Liquid Formulation). Stabilization of the Lead Antibody after reconstitution was assessed by
SEC for purity, and DLS and FCM for particle formation. The relevant criteria to discriminate
between formulations were:
18169100_1 (GHMatters) P41154NZ00
• The level of HMW 24h after reconstitution (storage at 5°C)
• The number of particles after mechanical stress.
Regarding HMW formation 24h after reconstitution (storage at 5°C), candidates
providing the best stability were (see Figure 22 and Figure 23):
• Phosphate with Mannitol 3 % + Glycine 1 %: #P14-6
• Tris/Phosphate with Sucrose 5 % + Proline 3 %: #P20-3
• Tris/Phosphate with Sucrose 5 % + Glycine 3 %: #P20-4
followed by:
• Phosphate with Sucrose 10 %: #P14-2
• Phosphate and Tris with Sucrose 5 % + Mannitol 3 %: #P14-3, P14-7 and P14-8
• Tris/Phosphate with Sucrose 5 % + Mannitol 3 %: #P20-1
To evaluate the stability of the lyophilisate, the reconstitution was done immediately after
manufacture and one month (assays #16-20) to two months (assays #18-20) afterwards. The
lyophilisate candidates were stored at 5°C (assay #16-20) and 20°C (assay #17). Stability of the
cake was assessed by SEC for purity, by FCM for particle formation, and by XRPD for cake
structure.
Regarding HMW and visible/sub-visible particle formation, all of the formulations were
found to be stable while stored at 5°C (see Figure 24 and Figure 25). The slight increase in
HMW level observed for both assays #17 and 20 after one month at 5°C was not reproduced in
the following assays (not shown). Furthermore, a slight increase in HMW level was observed
while stored at 20°C (see Figure 24).
FDS stability, which is an important parameter to ensure a DP of quality, was taken into
account for assays #16-18 and 20. Stabilization of the Lead Antibody at this stage of the process
was assessed by SEC for purity, and DLS and FCM for particles formation. Storage at 5°C was
found to be relevant to monitor the effect of the additives on the stability of the Lead Antibody.
One freeze/thaw cycle done on FDS was also relevant to discriminate between formulations.
Regarding stability of the Lead Antibody while stored at 5°C, results were described in
the Section regarding Additives (see Figure 14). The best stability was obtained for:
• Tris/Phosphate with Sucrose 1.75 % + Proline 1.05 %: #P20FDS
• Tris/Phosphate with Sucrose 1.75 % + Glycine 1.05 %: #P20FDS
followed by:
18169100_1 (GHMatters) P41154NZ00
• Tris/Phosphate with Sucrose 1.75 % + Mannitol 1.05 %: #P20FDS
Regarding stability of the Lead Antibody after one freeze/thaw cycle, particle counting done by
FCM showed that the following formulation candidates were stable:
• Tris/Phosphate with Sucrose 1.67 % + Mannitol 1 %: #P17FDS
• Tris/Phosphate with Sucrose 1.75 % + Mannitol 1.05 %: #P20FDS
• Tris/Phosphate with Sucrose 1.75 % + Proline 1.05 %: #P20FDS
In conclusion, considering the following criteria: stability of the Lead Antibody during
the process, aspect and stability of the cake as well as reconstitution time, stability of the
reconstituted solution and of the FDS, 2 formulation candidates clearly stand out:
• Tris/Phosphate with Sucrose 5 % + Mannitol 3%
• Tris/Phosphate with Sucrose 5% + Proline 3%
Conclusions for Examples 2-6
During the preformulation work, the formation of visible/sub-visible particles was
managed due to the selection of a range of pH (≥ 7.0), of a buffering system (Tris/Phosphate)
and especially to the addition of a surfactant: polysorbate 80 at a concentration of 0.2 %.
However, the formation of HMW was still an issue for a liquid formulation. Although
HMW formation was significantly reduced by the selection of optimal pH (7.0), and some
excipients (namely sucrose, mannitol, and amino acids such as glycine and proline), the
beneficial effect at 100 mg/mL did not sufficiently prevent formation of HMW to expect a
satisfactory shelf life for a liquid formulation.
Hence a lyophilised formulation was developed along with a lyophilisation process. To
prevent aggregation during the lyophilisation process, a cryoprotectant was selected: sucrose at a
concentration of 5%. The stabilizing excipients selected for the liquid formulation were tested in
the lyophilisation process to better stabilize both the liquid before lyophilisation (concentration:
mg/mL) and the reconstituted solution (concentration: 100 mg/mL). A few of these
excipients were compatible with the lyophilisation process and among them two have been
selected: mannitol and proline at a concentration of 3%. The main criteria for the selection were:
elegance and stability of the cake as well as stability of the FDS (solution before lyophilisation)
and of the reconstituted solution.
The two formulation put in long term stability differ from one excipient (see Table 23):
18169100_1 (GHMatters) P41154NZ00
• Prototype 1: Proline
• Prototype 2: Mannitol
Table 23 Description of the formulations
Compound Concentration Function
Lead Antibody 100 mg/mL Active ingredient
Tris/Phosphate 10 mM Buffer – pH 7.0
Polysorbate 80 0.2% (p/v) Stabilizing agent for visible/sub-visible particles
Sucrose 5% (p/v) Cryoprotectant + Stabilizing agent for HMW
Prototype 1: Proline 3% 3% (p/v) Stabilizing agent for HMW + Tonifiant agent
Prototype 2: Mannitol 3% 3% (p/v) Stabilizing agent for HMW + Tonifiant agent
ADDITIONAL FORMULATION STUDIES (Examples 7-8)
Abbreviations used in Examples 7-8 are:
DP: Drug Product
DS: Drug Substance
FD: Formulation Development
FDS: Formulated Drug Substance
FIM: First In Man
GRAS: Generally Recognized As Safe
HDPE: High Density Polyethylene
HMW: High Molecular Weight
IEF: IsoElectronic Focusing
IL: Interleukin
LMW: Low Molecular Weight
PC: Polycarbonate
PES: Polyethersulfone
PP: Polypropylène
PVDF: Polyvinylidene fluoride
RT: Room Temperature
SC: Sub Cutaneous
Td1: First Temperature of Denaturation
18169100_1 (GHMatters) P41154NZ00
TOR: Time Out of Refrigeration
Summary
The aim of these studies (Examples 7-8) was to improve the FDS stability regarding the
high propensity for HMW formation of the Lead Antibody in the liquid state.
The study plan was defined based on prior knowledge acquired in the pre-formulation
studies (Examples 2-6) and is focused on kinetics of HMW formation at room temperature, in the
FDS at 35 mg/mL.
All buffers and excipients used were already used either in marketed antibody products or
in other products for parenteral use, in particular they are all GRAS (Generally Recognized As
Safe). The pH ranges between 6.2 and 7.4.
A total of 50 different formations were compared side by side with the formulation
described Table 23. The main conclusions were:
• pH values around 6.2 decreases Lead Antibody solubility: a gel formation and a
precipitation were observed with Succinate and Histidine respectively
• In addition, Histidine should be avoided at pH 6.6 as the solution was opalescent and
slightly less thermally stable
• In the range of pH between 6.6 to 7.4, there was no clear pH effect on HMW
formation kinetic
• Increasing ionic strength had a destabilizing effect on HMW formation kinetics
• Phosphate and Citrate were the best buffers tested, provided they were at low
concentration such as 1.75 mM
• Among all the excipients tested, the best stabilizing effect was obtained with Glycine
and 72 mM, and Sucrose 2.4%. However, the stabilizing effect did not allow us to
significantly slow down the HMW formation
In conclusion, the results in Examples 7-8 did not identify a new combination of
excipients that could improve significantly the formulations described in Table 23 regarding
HMW formation. The recommendation was to keep the following formulation (see Table 24):
Phosphate 6.5 mM/Tris 3.7 mM, pH 7.0, PS80 0.2% (w/v), Sucrose 5% (w/v), Proline 3% (w/v).
18169100_1 (GHMatters) P41154NZ00
Table 24 Formulation description
Component Concentration
Lead Antibody 100 mg/mL
Phosphate 6.5 mM
Tris 3.7 mM
Sucrose 5% (w/v)
Proline 3% (w/v)
PS80 0.2% (w/v)
Introduction
The Lead Antibody is an engineered humanized bispecific antibody (BsAb) that targets
the cytokines IL-4 and IL-13. Its molecular weight, as determined by mass spectrometry, is 198
kDa, and its Ip, as determined by IEF ranges between 5.8 to 6.2.
Major manufacturing DS process changes are being implemented for phase IIb and a
comparability study is planned between phase I/IIa and phase IIb DS and DP quality. As part of
the DS manufacturing changes, it was decided to perform a formulation study with the aim to
reduce the HMW formation in the liquid state. Thus, the potential improvement of the
formulation could be included in the comparability study.
Note that in the same time, the DP manufacturing process for phase IIb is being
optimized for scale-up, FDS thawing, and DP dose/vial change to 100 mg/7 mL vial instead of
150 mg/15 mL vial. This study is being conducted in parallel with the formulation development.
The current target product profile for this study (Examples 7-8) stipulates the following
characteristics of the drug product:
• Route of administration: SC injection
• DP form: lyophilized
• Concentration: solution reconstituted at 100 mg/mL
• Shelf-life: 24 months
• Temperature of storage: 2°C-8°C
• Dose strength: 100 mg/vial
• Primary container: 7 mL type 1 tubing clear glass vial
18169100_1 (GHMatters) P41154NZ00
The drug substance should be formulated at 35 mg/mL prior to storage at -20°C in 1L
polycarbonate bottles. No additional excipients or dilutions are performed prior to freeze-drying.
Pre-formulation and formulation studies for FIM allowed the following conclusions:
• Avoid acidic pH < 6.0 (low thermal and colloidal stability) and basic pH > 7.5 (LMW
formation and charge isoforms change under thermal stress).
• Visible/sub-visible particles were significantly reduced by using polysorbate 80 at a
concentration of 0.2% in combination with the buffering system Phosphate/Tris, pH 7.0
• The HMW formation kinetic increases with Lead Antibody concentration, and the tested
formulations did not sufficiently prevent HMW formation at 100 mg/mL for us to expect
a satisfactory shelf life for a liquid formulation.
• HMW formation in the liquid state drove the development toward a lyophilized DP
reconstituted with slightly less than 1/3 of the initial volume (before lyophilisation) to
achieve 100 mg/mL from a 35 mg/mL FDS. A cryoprotectant and lyoprotectant were
selected: Sucrose at a concentration of 5%.
• The formulation selected for phase I and IIa was the following: Phosphate 6.5 mM/Tris
3.7 mM, pH 7.0, PS80 0.2% (w/v), Sucrose 5% (w/v), Proline 3% (w/v).
• This formulation might be optimized regarding HMW formation by combining the
excipients identified as having a slight positive effect, namely: Sucrose, Mannitol, and
amino acids such as Glycine and Proline.
HMW formation in the liquid state has been identified as being the major path of
degradation. The kinetic increases with the temperature of the solution (10 times slower at 5°C
than at RT in the DP) and with Lead Antibody concentration:
• FDS at 35 mg/mL at RT: ΔHMW= +1.6% in 7h and +4.1% in 24h
• DP at 100 mg/mL at RT: ΔHMW= +0.6% in 1h and +3.5% in 5h
Objectives
The objective of this study (Examples 7-8) was to increase the stability of the Lead
Antibody in the liquid state with respect to HMW formation. In order to set quantitative targets
for this study, the following values were proposed:
• 5h at RT after DP reconstitution for in-use stability: ΔHMW< +1% in 5h,
• 12h of TOR for the FDS in order to ease DP manufacture: ΔHMW< +1% in 12h.
18169100_1 (GHMatters) P41154NZ00
These target values take into account the conditions of use of the reconstituted DP at
100 mg/mL and the process manufacturing conditions when the FDS at 35 mg/mL is out of
refrigerated conditions. These values should be adjusted depending on the Quality Target
Product Profile.
Study Design
The approach proposed for this study (Examples 7-8) was to screen the combined
excipients over a wide range of formulations at Lead Antibody concentrations of 35 mg/mL.
The screening of formulations was focused on stabilizing excipients that could potentially
impact the HMW formation. It was decided for this study the following:
• PS80 and Sucrose at the formulation phase I concentrations were kept in the screening as
no negative impact on HMW formation at these concentrations had been demonstrated
and a strong positive impact on manufacturing process and/or reconstitution had been
observed.
• The pH range was tightened between 6.2 and 7.4 because previous studies had shown the
benefit of keeping the pH around pH 7
• The 5 injectable buffers within this pH range were screened, alone or in combination with
several excipients: other buffering systems and/or additives (amino acids, sucrose (in
addition to what was already contained in the phase I formulation) and salts mainly).
Drug substance
DS used in this study (Examples 7-8) are described Table 25.
Table 25 DS description
Batch Manuf. Concentr Used for
Type Manufacturer Formulation Storage
number # date ation assays
LTDS FDS Phosphate 2.22 mM/ 33 mg/mL -20°C H04-150 to
Tris 1.28 mM, Sucrose 190
1.75%, Proline 1.05%,
PS80 0.07%
VAB-YKR1- DS Sucrose 2.1% 42 mg/mL -20°C H04-193
000079
18169100_1 (GHMatters) P41154NZ00
Drug product
DP used in this study (Examples 7-8) were formulated with formulation phase I/IIa
(Phosphate 6.5 mM/Tris 3.7 mM, pH 7.0, PS80 0.2%, Sucrose 5%, Proline 3%) (see Table 26).
Table 26 DP description
DP Lyophilisate # Manuf. date Manufacturer Strength/Format From the FDS #
H04-016 150mg /15mL vial CER0315 and CER0375
H04-046 150mg /15mL vial CER0378, CER0382 and CER0392
C1016207 150mg /15mL vial GMP2
H04-193 100mg /7mL vial H04-193
Formula(S)
Formulas for each assay in Examples 7-8 are listed below in Table 27.
Table 27 Formula
Formulation Buffer system pH Nominal
Nominal composition of excipienta
assay # concentration
(mg/mL)
H04-150 A1 Succinate 10 mM 6.2 Sucrose 1.75% - PS80 0.07% 36.25
H04-150 A2 Succinate 10 mM 6.2 Tris 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 A3 Succinate 10 mM 6.2 Histidine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 A4 Succinate 10 mM 6.2 Proline 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 A5 Succinate 10 mM 6.2 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 A6 Succinate 10 mM 6.2 Tris 10 mM – Glycine 10 mM - Sucrose 1.75% - 36.25
PS80 0.07%
Preliminary test Histidine 10 mM 6.2 Sucrose 1.75% - PS80 0.07% 36.25
(P-H04-144)
Preliminary test
Histidine 10 mM 6.2 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
(P-H04-148)
H04-150 B1 Histidine 10 mM 6.6 Sucrose 1.75% - PS80 0.07% 36.25
H04-150 B2 Histidine 10 mM 6.6 Tris 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 B3 Histidine 10 mM 6.6 Proline 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 B4 Histidine 10 mM 6.6 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-150 C - 6.8 Sucrose 2.1% - PS80 0.07% 36.25
H04-150 D Phosphate 3.33 mM 6.9 Sucrose 8.42% - PS80 0.07% 36.25
/Tris 1.92 mM
H04-163 A1 Citrate 10 mM 6.6 Sucrose 1.75% - PS80 0.07% 36.25
H04-163 A2 Citrate 10 mM 6.6 Tris 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
18169100_1 (GHMatters) P41154NZ00
Formulation Buffer system pH Nominal
Nominal composition of excipienta
assay # concentration
(mg/mL)
H04-163 A3 Citrate 10 mM 6.6 Histidine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 A4 Citrate 10 mM 6.6 Proline 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 A5 Citrate 10 mM 6.6 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 A6 Citrate 10 mM 6.6 Tris 10 mM- Glycine 10 mM - Sucrose 1.75% - 36.25
PS80 0.07%
H04-163 B1 Phosphate 10 mM 6.6 Sucrose 1.75% - PS80 0.07% 36.25
H04-163 B2 Phosphate 10 mM 7.0 Sucrose 1.75% - PS80 0.07% 36.25
H04-163 B3 Phosphate 10 mM 7.0 Tris 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 B4 Phosphate 10 mM 7.0 Histidine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 B5 Phosphate 10 mM 7.0 Proline 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-163 B6 Phosphate 10 mM 7.0 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-172 A1 Tris 10 mM 7.0 Sucrose 1.75% - PS80 0.07% 36.25
H04-172 A2 Tris 10 mM 7.4 Sucrose 1.75% - PS80 0.07% 36.25
Succinate 10 mM NaCl 7.5 mM - Sucrose 1.75% - 36.25
H04-172 A3 Tris 10 mM 7.4
PS80 0.07%
H04-172 A4 Tris 10 mM 7.0 Histidine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-172 A5 Tris 10 mM 7.4 Histidine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-172 A6 Tris 10 mM 7.4 Glycine 10 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-172 B1 Phosphate 1.75 mM 7.0 Sucrose 1.75% - PS80 0.07% 36.25
H04-172 B2 Phosphate 1.75 mM 7.0 Sucrose 4% - PS80 0.07% 36.25
H04-185 A1 - 6.8 Sucrose 4.15% - PS80 0.07% 36.25
H04-185 A2 - 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 B1 Phosphate 1.75 mM 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 B2 Phosphate 1.75 mM 6.8 Sucrose 4.15% - PS80 0.07% 36.25
Sodium benzoate 37.8 mM - Sucrose 1.75% - 36.25
H04-185 B3 Phosphate 1.75 mM 6.8
PS80 0.07%
H04-185 B4 Phosphate 1.75 mM 6.8 NaCl 38.5 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 B5 Phosphate 5.25 mM 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 C1 Citrate 5.25 mM 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 C2 Citrate 1.75 mM 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 C3 Citrate 1.75 mM 6.8 Sucrose 4.15% - PS80 0.07% 36.25
H04-185 C4 Citrate 10 mM 6.8 Glycine 72 mM - Sucrose 1.75% - PS80 0.07% 36.25
Phosphate 2.22 mM Proline 91 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-185 D 6.8
/Tris 1.28 mM
Phosphate 2.22 mM Proline 91 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-187 A1 6.7
/Tris 1.28 mM
18169100_1 (GHMatters) P41154NZ00
Formulation Buffer system pH Nominal
Nominal composition of excipienta
assay # concentration
(mg/mL)
Phosphate 2.22 mM Proline 91 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-187 A2 6.8
/Tris 1.28 mM
Phosphate 2.22 mM Proline 91 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-187 A3 7.0
/Tris 1.28 mM
Phosphate 2.22 mM Proline 91 mM - Sucrose 1.75% - PS80 0.07% 36.25
H04-187 A4 7.2
/Tris 1.28 mM
H04-190 A1 - 6.8 Sucrose 20.5% - PS80 0.07% 20
H04-190 A2 - 6.8 Sucrose 13.42% - PS80 0.07% 36.25
H04-190 A2 - 6.8 Sucrose 1.75% - PS80 0.07% 36.25
a Excipients quantities are expressed in % of w/v
Manufacture Process
The formulations in Examples 7-8 were manufactured with a concentrated solution of
Lead Antibody that was obtained by UF/DF at a concentration of 42 mg/mL in sucrose 2.1%.
This Lead Antibody solution was diluted with concentrated stock solutions of excipients.
UF/DF process
During the UF/DF process (Examples 7-8), the initial protein solution at 35 mg/mL was
first concentrated to 40 mg/mL, the buffer was then exchanged. After the diafiltration, the
protein solution was concentrated higher than 42 mg/mL, which was the target final
concentration (see Table 28).
The material used and the process conditions of each UF/DF are described Table 28. At
the end of the UF/DF, the Lead Antibody concentration was adjusted to 42 mg/mL in a Sucrose
2.1% solution.
Table 28 UF/DF manufacturing parameters
Ratio: g of Protein Protein
Number of
protein / concentration concentration
Formulation diafiltration Buffer
Membrane m² during at the end of
assays # volume exchange
membrane diafiltration the UF/DF
passed
(g/m ) (mg/mL) (mg/mL)
Pellicon 3® Sucrose
H04-137 216 40 9 48.5
0.11 m² 2.1%
18169100_1 (GHMatters) P41154NZ00
Formulation adjustment
Lead Antibody post UF/DF solution (Examples 7-8) was diluted with appropriate
amounts of concentrated stock solutions up to the desired final formulation. The reference and
composition of the concentrated solutions manufactured for this study are summarized in Table
Table 29 Concentrated stock solution recipes
Formulation assay # Buffer system pH adjusted to
Nominal composition of excipient
P -H04-138 Succinate 60 mM
- 5.9
P -H04-139 Succinate 60 mM Tris 60 mM 5.9
P -H04-140 Succinate 60 mM Histidine 60 mM 6.2
P -H04-141 Succinate 60 mM Proline 60 mM 5.9
P -H04-142 Succinate 60 mM Glycine 60 mM 5.9
P -H04-143 Succinate 60 mM Tris 60 mM – Glycine 60 mM 5.9
P -H04-144 Histidine 60 mM - 6.1
P -H04-145 Histidine 60 mM - 6.6
P -H04-146 Histidine 60 mM Tris 60 mM 6.4
P -H04-147 Histidine 60 mM Proline 60 mM 6.5
P -H04-148 Histidine 60 mM Glycine 60 mM 6.1
P -H04-149 Histidine 60 mM Glycine 60 mM 6.6
(H04-150) Phos 20 mM /Tris 11.5 mM Sucrose 40% No adjustment
P -H04-151 Citrate 60 mM - 6.4
P -H04-152 Citrate 60 mM Tris 60 mM 6.3
P -H04-153 Citrate 60 mM Histidine 60 mM 6.6
P -H04-154 Citrate 60 mM Proline 60 mM 6.4
P -H04-155 Citrate 60 mM Glycine 60 mM 6.4
P -H04-156 Citrate 60 mM Tris 60 mM- Glycine 60 mM 6.2
P -H04-157 Phosphate 60 mM - 6.4
P -H04-158 Phosphate 60 mM - 7
P -H04-159 Phosphate 60 mM Tris 60 mM 6.9
P -H04-160 Phosphate 60 mM Histidine 60 mM 7
P -H04-161 Phosphate 60 mM Proline 60 mM 7
P -H04-162 Phosphate 60 mM Glycine 60 mM 6.8
P -H04-164 Tris 60 mM - 7.3
18169100_1 (GHMatters) P41154NZ00
Formulation assay # Buffer system pH adjusted to
Nominal composition of excipient
P -H04-165 Tris 60 mM - 7.7
P -H04-166 Tris 60 mM Succinate 60 mM NaCl 45 mM 7.7
P -H04-167 Tris 60 mM Histidine 60 mM 7.2
P -H04-168 Tris 60 mM Histidine 60 mM 7.5
P -H04-169 Tris 60 mM Glycine 60 mM 7.6
P -H04-170 Phosphate 10.5 mM - 7.2
P -H04-171 Phosphate 10.5 mM Sucrose 13.5% 7.2
P -H04-173 - Sucrose 14.4% No adjustment
P -H04-174 - Glycine 432 mM No adjustment
P -H04-175 Phosphate 10.5 mM Glycine 432 mM 6.8
P -H04-176 Phosphate 10.5 mM Sucrose 14.4% 6.8
P -H04-177 Phosphate 10.5 mM Sodium benzoate 227 mM 6.8
P -H04-178 Phosphate 10.5 mM NaCl 231 mM 6.8
P -H04-179 Phosphate 31.5 mM Glycine 432 mM 6.8
P -H04-180 Citrate 31.5 mM Glycine 432 mM 6.8
P -H04-181 Citrate 10.5 mM Glycine 432 mM 6.8
P -H04-182 Citrate 10.5 mM Sucrose 14.4% 6.8
P -H04-183 Citrate 60 mM Glycine 432 mM 6.8
P -H04-184 Phos 13.3 mM /Tris 7.7 mM Proline 547 mM 7
P -H04-186 Phos 13.3 mM /Tris 7.7 mM Proline 547 mM 6.5
P -H04-189 1 - Sucrose 37.5% No adjustment
P -H04-189 2 - Sucrose 70% No adjustment
a Excipients quantities expressed in % are in w/v
Each formulation was sterile filtered (Millex® GV) under laminar flow and a fraction
was dispensed into a 2 mL type I glass vial as appropriate (1 to 2mL) and stoppered for each
stability time point.
Stress Conditions
Thermal stress
The thermal stress conditions performed in Examples 7-8, according to formulation
assays, are listed in Table 30.
18169100_1 (GHMatters) P41154NZ00
Table 30 Thermal stress conditions
Formulation assays # Temperature stress Time of stress
Days: 1, 2 and 3
H04-150
Days: 2, 3 and 6
Days: 1, 2 and 3
H04-163
Days: 2, 3 and 7
Days: 1, 2, 3 and 6
H04-172
Days: 2, 3 and 6
Days: 1, 2 and 3
H04-185
Days: 2, 3 and 6
16h, 24h and 40h
H04-187
16h, 40h and 48h
H04-190
21h, 30h and 46h
H04-193
21h, 30h and 46h
°C
a Due to laboratory air conditioning, RT ranges between 21°C and 29°C
b Performed in a standard non GMP refrigerated chamber
c GMP thermostic chamber
Analytical methods description
The following analytical methods were performed in Examples 7-8:
• Visual inspection for appearance (clarity and color)
- Solution in 7 mL vials were observed with natural light
• HPLC-SEC for protein purity
- 2 Columns PROSEC 300S- 250 x 4.6 mm at 35°C
- Mobile phase: Phosphate 0.1 M/NaCl 0.2 M pH 7.0
- Detection: 280 nm
- Injection: 10 µL (concentration 5 mg/mL)
- Flow: 0.2 mL/min
- Total run time: 40 min
The following analytical method was performed:
• UPLC-SEC for protein purity
- Column: 1 Acquity BEH200 SEC (150 x 4.6 mm dp=1.7 µm) at 40°C
- Mobile phase: Na HPO 50 mM/NaClO 300 mM at pH 7.0
2 4 4
18169100_1 (GHMatters) P41154NZ00
- Detection: UV at 280 nm
- Injection: 1 µL (solution at 5 mg/mL) Standard 3014ET
- Injection: 2 µL (solutions at 2.0 mg/mL)
- Flow: 0.3 mL/min
- Total run time: 8 min
The following analytical method was monitored:
• DSC for temperature of denaturation:
- Differential Scanning Calorimetry (DSC) was used to estimate the thermal stability of
the antibody in different formulations.
- Calorimetric measurements were performed with a VP-Capillary DSC from 25°C to
100°C with a heating rate of 1°C/min.
- The capacity curve gave information about the denaturation temperature Td (°C)
(peak maximum).
Criteria of evaluation
• SEC: The results were considered comparable when the difference was equal or less than
0.5% of HMW.
• DSC: The results were considered comparable when the difference on Td1 was equal or
less than 0.4°C.
UPLC vs HPLC method
The first screening (assays #H04-150 to 172) had been performed on the HPLC method
developed for phase I. An issue regarding a drifting of the baseline that impacted HMW level
determination had been observed when a high number of samples were analyzed in a row.
For the second screening (assays #H04-185 to 190), in order to obtain a precise HMW
level evolution, a UPLC method was used for which no baseline drifting had been observed. The
same chromatographic profile of the standard was observed even after more than 200 samples
were injected on the same column.
18169100_1 (GHMatters) P41154NZ00
References for SEC measurements
In order to compare the different series regarding the HMW evolution over time, the
formulation phase I was used as a reference:
• For the first screening (assays #H04-150 to 172), the FDS phase I was obtained, for each
of the 3 series, by reconstitution with WFI at 35 mg/mL of DP lyophilisate #H04-016.
• For the second screening (assays #H04-185 to 190), in addition to the previous FDS
phase I (H04-016), another FDS phase I freshly manufactured along with the tested
formulations was used, for each of the 3 series. Furthermore, a 3 FDS phase I reference
(#LTDS) was used: the FDS not freeze-dried, but only thawed.
Unexpectedly, HMW kinetics appeared different between the various references. For
comparison, two additional DP lyophilisates had been tested along with the DP lyophilisate
#H04-016. The difference within the DP lyophilisate became significant after 40h at RT.
However, the thawed reference, #LTDS was significantly different from all of the DP
lyophilisate, from 16h at RT. The DP lyophilisate presented faster HMW kinetics than the
thawed reference, #LTDS, and thus can not be used to compare the formulations
manufactured in this study (formulations for this study were manufactured from thawed FDS
(see Section regarding Manufacture Process) to the formulation phase I/IIa.
Using the same batch and freshly prepared freeze-dried DP, no significant difference on
HMW kinetics was observed between the thawed FDS and the DP lyophilisate. Thus, the HMW
kinetics observed on the formulations freshly manufactured for this study would be observed as
well on the same formulations after freeze-drying.
The conclusion drawn from those assays can not be generalized to all DP lyophilisate and
all thawed FDS. The comparison of HMW kinetics between different batches may depend on
various parameters and will need a specific and separate study.
Results and Discussion
All formulations manufactured in Examples 7-8 contained at least 1.75% (w/v) of sucrose
and close to 0.07% (w/v) of PS80. These concentrations are nominal values and are based on the
dilution factor applied to the Lead Antibody starting solution. Regarding PS80 concentration,
18169100_1 (GHMatters) P41154NZ00
the assumption was made that PS80 adsorption during UF/DF was negligible. These excipient
concentrations were the same as the formulation phase I.
EXAMPLE 7 – BUFFER SCREENING
The pH in this example was screened from 6.2 to 7.4, and within this range all injectable
buffers had been tested: Succinate, Histidine, Citrate, Phosphate, and Tris.
A) Type of buffer and pH
In the first screening (assays #H04-150 to 172), the above buffers were tested at a
concentration of 10 mM, in combination with several excipients that will be further detailed in
Example 8 - Additives Screening. Note that the buffer concentration was fixed at 10 mM and
that its impact on HMW formation will be seen in the Section regarding Buffer Concentration
(Example 7).
DSC results showed that all formulations were comparable to the reference (Td1=
65.5°C), except for Histidine formulations, which were thermally slightly less stable (Td1=
64.7°C to 65.1°C) (see Figure 26).
Visual inspection at initial time
All formulations were limpid and comparable to the reference, except for formulations at
pH 6.2 and Histidine formulations at pH 6.6.
At pH 6.2, a decrease of solubility was observed for both tested buffers:
• Histidine formulations precipitate at RT (see Figure 27)
• Succinate formulations were slightly opalescent at RT and one can observ the formation
of a gel at 5°C (see Figure 27), which was reversible when the solution was returned to
RT and gently shaken. Succinate may have chelating properties.
Histidine formulations at pH 6.6 were slightly more opalescent at RT than the reference.
HMW evolution by SEC
18169100_1 (GHMatters) P41154NZ00
As the results presented here were from 3 different series, the HMW evolution can not be
compared directly, but only to the reference.
• Histidine pH 6.6 was comparable to the reference at RT and slightly better at 5°C (+2.4%
for Histidine alone and +3.2% in 144h for the reference).
• Citrate pH 6.6 was slightly better at RT than the reference (+4.6% for Citrate alone and
+5.2% in 24h for the reference) and comparable to the reference at 5°C.
• Phosphate pH 6.6 was slightly better at RT than the reference (+8.2% for Phosphate alone
and +9.0% in 48h for the reference) and comparable to the reference at 5°C.
• Phosphate pH 7 was comparable to the reference at RT and 5°C.
• Tris pH 7 was slightly worse than the reference at RT (+7.8% for Tris alone and +7.0% in
48h for the reference) and comparable to the reference at 5°C.
• Tris pH 7.4 was comparable to the reference at RT and 5°C.
See Figure 28.
Regarding HMW formation, at pH 6.6, Phosphate and Citrate were comparable, and at
pH 7.0, Phosphate was slightly more stabilizing than Tris. The above buffers at 10 mM can not
be directly compared to the formulation phase I/IIa, as the reference used for this screening was a
lyophilisate manufactured from another batch (see Section above regarding References for SEC
Measurements).
Conclusion
Regarding the buffering system screening at a concentration of 10 mM, it can be
conclude that:
• pH values around 6.2 (close to the pI) decreased Lead Antibody solubility:
- A gel formation was observed with Succinate at pH 6.2
A precipitation was observed with Histidine at pH 6.2
• In addition, Histidine should be avoided at pH 6.6 as the solution was opalescent and
slightly less thermally stable
• There is no clear tendency of pH effect within the range 6.6 to 7.4 on HMW formation
for the buffers tested: Histidine, Citrate, Phosphate and Tris
• Very weak effect of the buffer regarding HMW formation, although Citrate and
Phosphate appeared to be the best buffers at 10 mM
18169100_1 (GHMatters) P41154NZ00
B) Fine tuning of pH on phase I/IIa formulation
In order to determine on the same run the influence of pH on HMW formation, the pH
had been screened over the range 6.7 to 7.2 on the phase I formulation (assays #H04-187).
DSC results showed that all formulations were comparable to the reference (pH 7.0) (see
Figure 29).
HMW evolution by SEC
There was a slight tendency for decreasing HMW formation when increasing the pH
from 6.7 to 7.2 (see Figure 30), however this became significant only after 24h at RT (+4.1% for
pH 6.7 and +3.4% for pH 7.2).
Conclusion
With a buffer Phosphate 2.2 mM/Tris 1.3 mM (formulation phase I), there was a slight
effect of pH over the range 6.7 to 7.2 after 24h at RT. However, this effect was weak since it
was not significant for the first 16h. This confirmed the weak effect of pH on HMW formation
in this pH range.
C) Buffer concentration
Citrate and Phosphate were tested at smaller concentrations than 10 mM: 0, 1.75, and
.25 mM, in order to investigate the influence of buffer concentration on HMW formation
(assays #H04-185). The pH was set to an intermediate point in the tested range: pH= 6.8. All
formulations contained Glycine at 72 mM to adjust osmolality and, as said in the beginning of
Section regarding Results and Discussion, 1.75% Sucrose and around 0.07% PS80.
DSC results showed that all formulations were comparable to the reference (formulation
phase I) (see Figure 31). Note that Glycine with no buffer (185A2) was slightly less stable than
the other tested formulations (about 1°C difference in Td1).
18169100_1 (GHMatters) P41154NZ00
HMW evolution by SEC
For both buffers tested, there was a slight tendency for decreasing HMW formation when
decreasing buffer concentrations, the best results were obtained with no buffer and 1.75mM in
buffer (for e.g., +7.8% for Citrate 10 mM and +7.0% for no buffer in 48h at RT) (see Figure 32).
Citrate at 1.75 mM and no buffer were comparable to the reference (for e.g., +7.1% for Citrate
and +7.0% for no buffer in 48h at RT whereas +6.8% for the reference).
Conclusion
Decreasing the buffer concentration had a slightly stabilizing effect on HMW formation
kinetics. This effect was probably related to ionic strength. No buffer and a buffer Citrate
1.75 mM were the best candidates in term of HMW formation, followed closely by Phosphate
1.75 mM. Those buffers tested with Glycine 72 mM were comparable to the formulation phase
I/IIa.
EXAMPLE 8 – ADDITIVES SCREENING
Screening of the additives Glycine, Proline, Histidine, and Tris had been done in
combination with the buffer screening (first screening: assays #H04-150 to 172) in order to
determine potential synergies between the excipients. Screening of the additives Sodium
chloride, Sodium benzoate, Glycine, and Sucrose (second screening: assays #H04-185 to 190)
had been done on Phosphate or Citrate, the best selected buffers from the first screening
(Example 7).
The formulations contained 1.75% Sucrose and around 0.07% PS80.
A) Sodium chloride and Sodium benzoate
Sodium chloride and Sodium benzoate were tested to evaluate the effects of ionic
strength and hydrophobic interactions, respectively, on HMW formation. These additives were
tested on Phosphate 1.75 mM pH 6.8 at a concentration not exceeding the formulation phase I
osmolality (165 mOsm/kg in the FDS).
18169100_1 (GHMatters) P41154NZ00
DSC results showed that NaCl formulation was comparable to the reference (Td1=
65.7°C for NaCl and 65.6°C for the reference) whereas sodium benzoate formulation was
thermally slightly less stable (Td1= 65.0°C).
HMW evolution by SEC
For both additives tested, there was a clear negative effect on HMW formation compared
to the reference (for e.g., +5.2% for NaCl at 38.5mM, +5.2% for sodium benzoate at 37.8 mM
and +3.2% for the reference in 24h at RT). The evolution being similar for both excipients, only
NaCl results are shown here (see Figure 33).
Conclusion
As seen for the buffer concentration, increasing ionic strength with NaCl or sodium
benzoate had a clear negative effect on HMW formation kinetics. Furthermore, the effect of
hydrophobic interactions on HMW kinetics, due to the addition of sodium benzoate was not
observed.
B) Glycine, Proline, Histidine and Tris
Theses additives (glycine, proline, histidine, and Tris) were tested at a concentration of
mM (first screening: assays #H04-150 to 172).
DSC results showed that all formulations with the above additives were comparable to
the formulation without (buffer alone).
HMW evolution by SEC
The differences between formulations were weak, although tendencies could be seen after
48h at RT and 6 days at 5°C:
• Histidine buffer:
- At RT: Ø (no additives) = Glycine > Proline > Tris
- At 5°C: Ø > Glycine = Proline > Tris
18169100_1 (GHMatters) P41154NZ00
• Citrate buffer:
- At RT: Glycine > Proline = Histidine = Tris = (Tris + Glycine) > Ø
- At 5°C: Glycine > Proline = Histidine = Tris = (Tris + Glycine) = Ø
• Phosphate buffer:
- At RT: Glycine = Proline = Ø > Histidine = Tris
- At 5°C: Glycine > Proline = Ø = Histidine = Tris
• Tris buffer:
- At RT: Glycine > Ø = Histidine
- At 5°C: Glycine = Ø = Histidine
Conclusion
Regarding HMW formation, the effects of these additives were weak, although
tendencies could be seen:
• Glycine at 10 mM had a slight positive effect
• Histidine and Proline at 10 mM seemed to have no effect
• Tris at 10 mM had no stabilizing effect and could even have a slight destabilizing effect
C) Sucrose and Glycine
In the second screening (assays #H04-185), an additional quantity of Sucrose of 2.4% (in
addition to the already 1.75% of Sucrose contained in all formulations, which gave a total of
4.15% (w/v) of Sucrose) and Glycine at a concentration of 72 mM were tested on the best
selected buffers (see Section regarding Buffer Screening). These concentrations were
maximized in order not to exceed the formulation phase I osmolality (165 mOsm/kg in the FDS).
DSC results showed that all Sucrose 2.4% and Glycine 72mM formulations were
comparable to the reference (for e.g., in the case of Sucrose, Td1= 65.7°C for Phosphate
1.75 mM and 65.6°C for the reference).
HMW evolution by SEC
18169100_1 (GHMatters) P41154NZ00
The slight positive impact of Glycine was confirmed when compared to only Sucrose
containing formulations for Citrate 1.75 mM and no buffer (see Figure 34). However, this
positive impact was only significant after 48h at RT.
Conclusion
Regarding HMW formation, on the timescale of interest (< 24h at RT), Sucrose and
Glycine formulations tested on the best buffer candidates were comparable to the formulation
phase I.
Conclusions for Examples 7-8
For this study, around 50 formulations had been manufactured and compared side by side
with the current phase I/IIa formulation. The pH screening ranged from 6.2 to 7.4, involving all
injectable buffers within this pH range, alone or in combination with several excipients (all
GRAS) in order to assess potential synergies between excipients.
Here were the main conclusions:
• pH values around 6.2 decrease Lead Antibody solubility: a gel formation and a
precipitation were observed with Succinate and Histidine respectively;
• In addition, Histidine should be avoided at pH 6.6, as the solution was opalescent and
slightly less thermally stable;
• In the range of pH between 6.6 to 7.4, there was no clear pH effect on HMW formation
kinetics;
• Increasing ionic strength had a destabilizing effect on HMW formation kinetics;
• Phosphate and Citrate were the best buffers tested, provided they were at low
concentration such as 1.75 mM;
• Among all the excipients tested, the best stabilizing effect had been obtained with
Glycine 10 and 72 mM, and Sucrose 2.4%. However the stabilizing effect did not permit
us to significantly slow down the HMW formation; and
• Proline, which has no effect at 10 mM, could be used as an isotonic agent (the effect of
Proline at 91 mM (Proline concentration in the FDS phase I formulation) had not been
18169100_1 (GHMatters) P41154NZ00
assessed regarding HMW formation (e.g., assessing FDS formulation phase I with and
without Proline).
In conclusion, the results of Examples 7-8 did not identify a new combination of
excipients that could improve significantly the current formulation regarding HMW formation.
That is, the results in Examples 7-8 confirm the results in Examples 1-6. The recommendation
was to keep the current phase I/IIa formulation for phase IIb studies. The current formulation
was therefore the following (see Table 31): Phosphate 6.5 mM/Tris 3.7 mM, pH 7.0, PS80 0.2%
(w/v), Sucrose 5% (w/v), Proline 3% (w/v).
Table 31 Phase I/ IIa/ IIb Formulation description
Component Concentration
Lead Antibody 100 mg/mL
Phosphate 6.5 mM
Tris 3.7 mM
Sucrose 5% (w/v)
Proline 3% (w/v)
PS80 0.2% (w/v)
A quantitative adjustment of the current formulation (fine tuning of the excipient
concentrations without adjunction of new excipients) may be performed for the phase
III/commercial formulation.
18169100_1 (GHMatters) P41154NZ00
Claims (13)
1. A stable antibody formulation comprising: 100 mg/mL of a bispecific anti-IL-4/anti-IL-13 antibody, comprising a light chain of the formula VL1-linker-VL2 and a heavy chain of the formula VH1-linker-VH2, wherein VL1 and VH1 form an IL-13 antigen binding domain and VL2 and VH2 form an IL-4 antigen binding domain, wherein VL1 comprises the amino acid sequence of SEQ ID NO: 1; VH1 comprises the amino acid sequence of SEQ ID NO: 2; VL2 comprises the amino acid sequence of SEQ ID NO: 3; and VH2 comprises the amino acid sequence of SEQ ID NO: 4 or 5; and a buffering system suitable to maintain the pH of the formulation at pH 7, wherein the buffering system comprises Tris buffer and phosphate buffer and wherein the formulation has a salt concentration of 10 mM in order to reduce the ionic strength of the formulation; 0.05% to 0.2% (w/v) polysorbate 80 at a concentration; 5% (w/v) sucrose; and 1% to about 3% (w/v) mannitol.
2. The formulation of claim 1, wherein the light chain comprises the formula N-VL1-linker-L2- CL, wherein CL is a light chain constant domain of an antibody, and wherein the heavy chain comprises the formula N-VH1-linker-VH2-CH1-CH2-CH3, wherein CH2-CH3 corresponds to the Fc domain of an antibody.
3. The formulation of claims 1 or 2, wherein the linker comprises the amino acid sequence of SEQ ID NO: 6.
4. The formulation of any one of claims 1 to 3, wherein the antibody thereof further comprises a constant region domain. 18169100_1 (GHMatters) P41154NZ00
5. The formulation of claim 4, wherein the constant region domain is selected from the group consisting of CH1, CH2, CH3, and CL.
6. The formulation of any one of claims 1 to 5, wherein the bispecific antibody is a humanized IgG4 bispecific antibody.
7. The formulation of any one of claims 1 to 6, wherein the Tris buffer concentration is 3.7 mM.
8. The formulation of any one of claims 1 to 7, wherein the Phosphate buffer concentration is 6.3
9. The formulation of any one of claims 1 to 8, wherein the polysorbate 80 concentration is 0.2% (w/v).
10. The formulation of any one of claims 1 to 9, wherein the mannitol concentration is 3% (w/v).
11. The formulation of any one of claims 1 to 10, wherein the formulation is a lyophilized formulation.
12. The formulation of any one of claims 1 to 11, wherein the formulation comprises: 100 mg/mL of a bispecific antibody, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 2 and 4, and a light chain variable region comprising the amino acid sequences of SEQ ID NOs: 1 and 3; 10 mM of a buffering system, wherein the buffering system comprises a Tris buffer concentration of 3.7 mM and a phosphate buffer concentration of 6.3 mM; 0.2% (w/v) polysorbate 80; 5% (w/v) sucrose; and 3% (w/v) mannitol; 18169100_1 (GHMatters) P41154NZ00 wherein the pH of the formulation is pH 7.
13. Use of the formulation of any one of claims 1 to 12 in the manufacture of a medicament for the treatment of an allergic disease, cancer, asthma, a disease associated with abnormal production of IL-4 and/or IL-13, or a disease associated with an elevated TH-2 mediated response. 18169100_1 (GHMatters) P41154NZ00
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361816899P | 2013-04-29 | 2013-04-29 | |
US61/816,899 | 2013-04-29 | ||
EP14305160.5 | 2014-02-05 | ||
EP14305160 | 2014-02-05 | ||
PCT/EP2014/058733 WO2014177568A1 (en) | 2013-04-29 | 2014-04-29 | Anti-il-4/anti-il-13 bispecific antibody formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ713782A NZ713782A (en) | 2021-11-26 |
NZ713782B2 true NZ713782B2 (en) | 2022-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014261497B2 (en) | Anti-IL-4/anti-IL-13 bispecific antibody formulations | |
JP6272950B2 (en) | Antibody preparation | |
US20200297855A1 (en) | Stable, aqueous formulations of antibodies that bind il5 receptor | |
US20150225479A1 (en) | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations | |
EP2830658B1 (en) | Stable igg4 binding agent formulations | |
NZ713782B2 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
ES2795993T3 (en) | Anti-IL-4 / Anti-IL-13 Bispecific Antibody Formulations | |
JP6820823B2 (en) | Stable IgG4-based binder formulation | |
BR112015027193B1 (en) | STABLE ANTIBODY FORMULATIONS, THEIR USE AND KIT |